Studies	Dystrophin IHC staining using FFPE muscle sections

Rod domain (DYS1)	C-terminus (DYS2)	N-terminus (DYS3)

Present study	Successful	Successful	Unsuccessful

Hoshino et al. 2000 [17]	Successful	Successful	Unsuccessful

Sheriffs et al. 2001 [18]	Successful	Successful	Successful

Sajid et al. 2010 [19]	Not performed	Successful	Not performed

Studies	Dystrophin IHC staining using FFPE muscle sections

Rod domain (DYS1)

Present study	Successful

Hoshino et al. 2000 [17]	Successful

Sheriffs et al. 2001 [18]	Successful

Sajid et al. 2010 [19]	Not performed

Dystrophin IHC staining using FFPE muscle sections

C-terminus (DYS2)	N-terminus (DYS3)

Successful	Unsuccessful

Successful	Unsuccessful

Successful	Successful

Successful	Not performed


Block 1	SNPs		Frequency of the haplotype

	rs915941	rs915942	population	Group A	Group B	Males	Females	Males	Group B

						Group A	Group A	Group B	Females

Haplotypes	A	G	0.880	0.890	0.870	-	0.870	0.878	0.871

C	A	0.119	0.110	0.124	-	0.120	0.122	0.126

Block 2	SNPs					Frequency of the haplotype

	rs2071429	rs2230037	rs4898389	rs5986877	rs7879049	Population (0.64)	Group A (0.73)	Group B (0.77)	Males Group A (N/R)	Females Group A (0.77)	Males Group B (0.76)	Females Group B (0.48)

Haplotypes	A	G	A	C	A	0.545	0.553	0.540	0.475	0.540	0.585	0.516

	G	A	G	G	G	0.402	0.394	0.407	0.475	0.365	0.364	0.431

	G	G	G	G	A	0.034	0.033	0.034	0.013	0.041	0.028	0.038


	Fatigue	Abdominal complaints	Musculo- skeletal complaints	Weight changes	Itch

Alkaline Phosphatase (AF)	x	x		x

Alanine aminotransferase (ALAT)	x	x		x	x

Amylase		x		x

Anti-endomysium		x		x

Aspartate aminotransferase (ASAT)	x	x		x

Bilirubin					x

Erythrocyte sedimentation rate (ESR)	x	x	x	x	x

Carbohydrate-deficient transferrin (CDT)	x	x		x	x

Creatinin kinase (CK)			x

Creatinin	x	x	x	x	x

C-reactive protein (CRP)		x

Differentiated leukocyte count	x	x		x	x

Eosinophils					x

Ferritin	x	x	x	x

Gamma glutamyl transferase (GGT)	x	x		x	x

Glucose	x	x	x	x	x

Haemoglobin (Hb)	x	x	x	x	x

Potassium (K)	x		x

Latex fixation test			x

Lactate dehydrogenase (LDH)	x			x

Leukocyte count	x	x		x	x

Monosticon	x

Total IgE		x			x

Thyroid stimulating hormone (TSH)	x	x	x	x	x

Transferrin saturation (TS)	x	x	x	x

Urea					x

Uric acid			x

Total number of tests	17	18	11	17	14

	Fatigue	Abdominal complaints	Musculo- skeletal complaints	Weight changes	Itch

Alkaline Phosphatase (AF)	x	x		x

Alanine aminotransferase (ALAT)	x	x		x	x

Amylase		x		x

Anti-endomysium		x		x

Aspartate aminotransferase (ASAT)	x	x		x

Bilirubin					x

Erythrocyte sedimentation rate (ESR)	x	x	x	x	x

Carbohydrate-deficient transferrin (CDT)	x	x		x	x

Creatinin kinase (CK)			x

Creatinin	x	x	x	x	x

C-reactive protein (CRP)		x

Differentiated leukocyte count	x	x		x	x

Eosinophils					x

	x

Ferritin		x	x	x

Gamma glutamyl transferase (GGT)	x	x		x	x

Glucose	x	x	x	x	x

Haemoglobin (Hb)	x	x	x	x	x

Potassium (K)	x		x

Latex fixation test			x

Lactate dehydrogenase (LDH)	x			x

Leukocyte count	x	x		x	x

Monosticon	x

Total IgE		x			x

Thyroid stimulating hormone (TSH)	x	x	x	x	x

Transferrin saturation (TS)	x	x	x	x

Urea					x

Uric acid			x

Total number of tests	17	18	11	17	14


Variable	Single etiologic agent(n = 126)	Multiple etiologic agents(n = 153)	P-value

Gram-positive cocci

Aerobic

 Staphylococcus aureus

Methicillin-susceptible S. aureus	27 (21.4)	15 (9.8)	0.007*

Methicillin-resistant S. aureus	20 (15.9)	34 (22.2)	0.182

 Coagulase-negative Staphylococcus	2 (1.6)	11 (7.2)	0.042*

 Streptococcus

Beta-hemolytic (Group A)	13 (10.3)	24 (15.7)	0.188

Beta-hemolytic (Group B)	2 (1.6)	4 (2.6)	0.693

Non-group A or B	-	2 (0.7)	-

S. viridans	2(1.6)	36 (23.5)	<0.001*

 Enterococcus faecalis	1(0.8)	45 (29.4)	<0.001*

Anaerobic

 Peptostreptococcus	-	38 (13.6)	-

Gram-positive rods

Aerobic

 Corynebacterium	-	8 (2.9)	-

Anaerobic

 Clostridium spp.	-	5 (1.8)	-

Gram negative rods

Aerobic

 Acinetobacter baumannii	3 (2.4)	20 (13.1)	0.001*

 Aeromonas spp.	11 (8.7)	11 (7.2)	0.635

 Citrobacter spp.	2 (1.6)	9 (5.9)	0.119

 E.coli.	2 (1.6)	35 (22.9)	<0.001*

 Enterobacter spp.	1 (0.8)	19 (12.4)	<0.001*

 Klebsiella pneumoniae	13 (10.3)	28 (18.3)	0.061

 Pseudomonas aeruginosa	3 (2.4)	16 (10.5)	0.008*

 Vibrio spp.	21 (17.5)	-	-

 Eikenella corrodens	-	4 (2.6)	-

 Klebsiella oxytoca	-	3 (2.0)	-

 Proteus mirabillis	-	23 (15.0)	-

 Serratia marcescens	-	7 (4.6)	-

 Other gram negative rods	1 (0.8)	15 (9.2)	0.002*

Anaerobic

 Prevotella spp.	2 (1.6)	10 (6.5)	0.071

 Bacteroides fragilis	-	15 (9.8)	-

 Fusobacterium	-	1 (0.7)	-

 Veillonella	-	3 (2.0)	-

Fungus	-	6 (3.9)	-


Formulation	Aromatic Content in Polymer (%)	EE (%)	LC (%)

Cur-Nano1	0	61.3 ± 0.5	6.8 ± 0.1

Cur-Nano2	25	61.3 ± 0.1	6.8 ± 0.0

Cur-Nano3	100	113.8 ± 3.4	12.6 ± 0.4


Outcome	Perceived labour ≥24 hours	Perceived labour <24 hours	RR (95% CI)

	n = 434	n = 813

	n (%)	n (%)

Mode of birth

Vaginal	189 (43.5)	412 (50.7)	0.86 (0.76-0.98)

Forceps or vacuum	122 (28.1)	237 (29.2)	0.96 (0.80–1.16)

Cesarean birth	123 (28.3)	164 (20.2)	1.40 (1.15-1.72)

Primary indication for cesarean

Dystocia/CPD	99 (80.5)	122 (74.4)	1.08 (0.95-1.23)

Fetal Distress	24 (19.5)	42 (25.6)	0.76 (0.49–1.19)

Length of time from admission to birth (minutes, mean ± sd)	714.6 ± 467.9	580.7 ± 441.6	p < .001

Length of first stage (minutes, mean ± sd)	916.1 ± 501.0	775.5 ± 417.8	p < .001

Length of second stage (minutes, mean ± sd)	125.3 ± 92.5	118.1 ± 97.8	ns

Cervical dilation on admission ≤ 3 cm	223 (52.0)	347 (43.3)	1.21 (1.07-1.36)


Laboratory ID	Laboratory type	Correct diagnosis

All Specimens, n (%)	Smear-Positive Specimens, n (%)	Smear-Negative Specimens, n (%)

1	Network	3 (42.9)	2 (33.3)	1 (100)

2	Network	7 (100)	6 (100)	1 (100)

3	Standalone	1 (14.3)	0 (0)	1 (100)

4	Standalone	1 (14.3)	0 (0)	1 (100)

5	Network	1 (14.3)	0 (0)	1 (100)

6	Standalone	6 (85.7)	6 (100)	0 (0)

7	Network	7 (100)	6 (100)	1 (100)

Indus Hospital	N/A	7 (100)	6 (100)	1 (100)

Laboratory ID	Laboratory type	Correct diagnosis

All Specimens, n (%)	Smear-Positive Specimens, n (%)	Smear-Negative Specimens, n (%)

1	Network	3 (42.9)	2 (33.3)	1 (100)

2	Network	7 (100)	6 (100)	1 (100)

3	Standalone	1 (14.3)	0 (0)	1 (100)

4	Standalone	1 (14.3)	0 (0)	1 (100)

5	Network	1 (14.3)	0 (0)	1 (100)

	Sta		6 (100	0 (0


Reference/reference number	Surrogate product	Countries	Study population	Method

Green [59]	Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel	Uganda	131 women; 21 men	Qual

Jones [33]	Astroglide Silken Secret (high-viscosity gel), KY Jelly (low-viscosity gel), Lubrin (suppository)	Zambia	301 women	Quant

Martin [15]	Gel	Thailand	23 women; 28 men	Qual

Montgomery [20]	Gel	South Africa, Tanzania, Uganda, Zambia	45 couples	Qual

Pool [48]	Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel	Uganda	138 women; 42 men	Qual

Salter [43]	Gel	Malawi	1686 women; 21 men	Mixed

Tanner [21]	Silken Secret vaginal moisturizer	USA	40 women	Qual

van der Straten [61]	Ring	South Africa, Tanzania	157 women; 19 men	Qual

Weeks [74]	Vaginal moisturizer	USA	546 women interviewed/surveyed; 94 participating in surrogate trial	Mixed

Reference/reference number	Surrogate product	Countries	Study population	Method

Martin [15]	Gel	Thailand	23 women; 28 men	Qual

Montgomery [20]	Gel	South Africa, Tanzania, Uganda, Zambia	45 couples	Qual

Pool [48]	Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel	Uganda	138 women; 42 men	Qual

Salter [43]	Gel	Malawi	1686 women; 21 men	Mixed

Tanner [21]	Silken Secret vaginal moisturizer	USA	40 women	Qual

van der Straten [61]	Ring	South Africa, Tanzania	157 women; 19 men	Qual

Weeks [74]	Vaginal moisturizer	USA	546 women interviewed/surveyed; 94 participating in surrogate trial	Mixed


Research Authors (Year)	Purpose	Characteristics	Outcomes

Alwan et al. [110] (2006)	Fall detection	The authors used dummies of humans to simulate original fall events. The experimental tests of falls were performed on concrete floors. A dummy was used to emulate the scenario of a person falling while attempting to get out of a chair. Another dummy was used to emulate the scenario of a person falling with upright position. The experiments were repeated three times with the same dummies.	100% accuracy.

Lombardi et al. [111] (2015)	Movement detection	A data model was proposed for storing and processing floor data. The proposed approach focused on estimating the center of floor pressure based on the widely used biomechanical concept of ground reaction force. Some practical tests on a real sensing floor prototype were attempted. The novel approach outperformed the traditional background subtraction schemas for the correct detection and tracking of people.	97% accuracy.

Serra et al. [112] (2014)	Footstep recognition	An easy-to-install and unobtrusive smart flooring system was proposed based on piezoelectric polymer floor sensors. The smart flooring system was utilized for efficient human footsteps recognition based on the Pearson product–moment correlation coefficient between the testing and reference signals for similarity calculation.	99% accuracy.

Research Authors (Year)	Purpose	Characteristics	Outcomes

Alwan et al. [110] (2006)	Fall detection	The authors used dummies of humans to simulate original fall events. The experimental tests of falls were performed on concrete floors. A dummy was used to emulate the scenario of a person falling while attempting to get out of a chair. Another dummy was used to emulate the scenario of a person falling with upright position. The experiments were repeated three times with the same dummies.	100% accuracy.

	Move	A data model was proposed for storing and processing floor data. The proposed approach focused on estimating the center of floor pressure based on the widely used biomechanical concept of ground reaction force. Some practical tests on a real sensing floor prototype were attempted. The novel approach outperformed the traditional background su	97% acc

Lombardi et al. [111] (2015)	ment detection	btraction schemas for the correct detection and tracking of people.	uracy.

Serra et al. [112] (2014)	Footstep recognition	An easy-to-install and unobtrusive smart flooring system was proposed based on piezoelectric polymer floor sensors. The smart flooring system was utilized for efficient human footsteps recognition based on the Pearson product–moment correlation coefficient between the testing and reference signals for similarity calculation.	99% accuracy.


	LDA	SVM (Linear)

Accuracy	Precision	Recall	Accuracy	Precision	Recall

Forehead_axis + Mouth_axis	77.8	76.9	66.7	77.8	76.9	66.7

Forehead_axis + Mouth_region	66.7	46.2	54.6	63.9	46.2	50.0

Forehead_region + Mouth_axis	88.9	92.3	80.0	88.9	92.3	80.0

Forehead_region + Mouth_region	75.0	85.7	63.2	77.8	84.6	64.7

	LDA	SVM (Linear)

Accuracy	Precision	Recall	Accuracy	Precision	Recall

Forehead_region + Mouth_region	75.0	85.7	63.2	77.8	84.6	64.7


Species	No tested	No of positive humans, buffaloes and a lion (Prevalence)

		RBPT	BAPA	Riv.T	95 % CI	TITER

		No	% positive	No	%Positive	No	% positive

Humans	340	5	1.5	2	0.6	2	0.6	0.1, 2.1	1:200*

Buffaloes	38	4	10.5	3	7.9	3	7.9	1.7, 21.4	1:200*

Lion	2	1	1/2	1	1/2	1	1/2		1:200*

Zebra	2	0	0	0		0	0

Species	No tested	No of positive humans, buffaloes and a lion (Prevalence)

		RBPT	BAPA	Riv.T	TITER

		No	% positive	No	%Positive	No	% positive

Lion	2	1	1/2	1	1/2	1	1/2	1:200*

Zebra	2	0	0	0		0	0


Characteristic	Value

Age, years

 Mean ± SD 	58.2 ± 13.6

 Range	30–92

Sex, % (n)

 Male	78.1 (25)

 Female	21.9 (7)

Race/ethnicity % (n)

 Caucasian/white	59.4 (19)

 African-American/black	31.3 (10)

 Asian/Pacific Islander	9.4 (3)

Marital status, % (n)

 Married	28.1 (9)

 Single	40.6 (13)

 Other (widowed/divorced)	31.3 (10)

Smoking

History of smoking, % (n)	75.0 (24)

Pack years, mean ± SD	21.0 ± 20.7

History of hypertension, % (n)	71.9 (23)

Creatinine on admission (g/dL), mean ± SD	1.9 ± 1.7

Etiology of heart failure, % (n)

 Ischemic	28.1 (9)

 Idiopathic	65.6 (21)

 Unknown/other	6.3 (2)

Ejection fraction <40%, % (n)	71.9 (23)

ACEi/ARB use—study end, % (n)	62.5 (20)

Beta blocker use—study end, % (n)	78.1 (25)

High-risk diagnoses for the elderly scale

 Low (0) = 9.5% chance dying in 1 year	0 (0)

 Intermediate (1-2) = 31% chance	53.1 (17)

 High risk (3–5) = 46% chance	31.3 (10)

 Very high risk (≥6) = 74% chance	15.6 (5)

Length of hospital stay, days

 Mean ± SD	9.5 ± 9.9

 Median	6.5

 Range	1–41

Physical therapy—in hospital, % (n)	34.4 (11)

LVAD received during study admission, % (n)	6.3 (2)

Discharged with physical therapy, occupational therapy, or home health, % (n)	40.6 (13)

Cardiac events—90 days after discharge, % (n)

 Cardiac readmission	34.4 (11)

 Heart transplant 	3.1 (1)

 Mortality	9.4 (3)

Characteristic	Value

Length of hospital stay, days

Mean ± SD	9.5 ± 9.9

Median	6.5

Range	1–41

Physical therapy—in hospital, % (n)	34.4 (11)

LVAD received during study admission, % (n)	6.3 (2)

Discharged with physical therapy, occupational therapy, or home health, % (n)	40.6 (13)

Cardiac events—90 days after discharge, % (n)

Cardiac readmission	34.4 (11)

Heart transplant	3.1 (1)

Mortality	9.4 (3)


	Before treatment	After 1 month	P value	After 6 months	P value	After 12 months	P value	Follow-up	P value

Group A Peg-IFN α + RBV + placebo (n = 31)

Work ability index	36.9 ± 5.2	21.4 ± 5.3	<0.01	37.8 ± 5.9	NS	38.7 ± 5.8	NS	39.8 ± 6.7	<0.001


	MMQL-UK (PF) component

MMQL-UK (CF) component	Physical Appearance	School	Social Functioning	Emotional Functioning	Physical Functioning

Physical Appearance	0.51**	0.05	0.20**	0.25**	0.12**

School	0.13**	0.56**	0.22*	0.14**	0.21**

Social Functioning	0.14**	0.10*	0.31**	0.23**	0.18**

Emotional Functioning	0.35**	0.20**	0.26**	0.38**	0.25**

Physical Activities	0.33**	0.25**	0.21**	0.27**	0.61**


 	Georgia	Cobb County, GA	Dekalb County, GA	Fulton County, GA	Gwinnett County, GA

Total Asian	320,905	31,164	37,095	52,213	86,957

Chinese (except Taiwanese)	44,604	4,961	5,767	10,025	10,624

Taiwanese	3,483	378	525	959	886


Disinfectant	Concentrations tested (contact time in minutes used)	Effective	Level of Evidence	Comments	Reference

Chlorhexidine gluconate	<0.02% (1440), 0.5% (0.5), 2% (2), 4% (3, 180, 1800)	Yes	Good	Most studied antiseptic. Limited clinical evaluation.	Schelenz et al., 2016; Abdolrasouli et al., 2017; Moore et al., 2017; Sherry et al., 2017

Chlorhexidine gluconate in isopropyl alcohol	2%/70% (2)	Yes	Low	In vitro testing only.	Moore et al., 2017

Povidone-iodine	10% (2, 3, 180, 1800)	Yes	Moderate	In vitro testing only.	Abdolrasouli et al., 2017; Moore et al., 2017;

Alcohol	70%	Yes	Low	Limited clinical evaluation.	Biswal et al., 2017

Disinfectant	Concentrations tested (contact time in minutes used)	Effective

Chlorhexidine gluconate	<0.02% (1440), 0.5% (0.5), 2% (2), 4% (3, 180, 1800)	Yes

Chlorhexidine gluconate in isopropyl alcohol	2%/70% (2)	Yes

Povidone-iodine	10% (2, 3, 180, 1800)	Yes

Alcohol	70%	Yes

Level of Evidence	Comments	Reference

Good	Most studied antiseptic. Limited clinical evaluation.	Schelenz et al., 2016; Abdolrasouli et al., 2017; Moore et al., 2017; Sherry et al., 2017

Low	In vitro testing only.	Moore et al., 2017

Moderate	In vitro testing only.	Abdolrasouli et al., 2017; Moore et al., 2017;

Low	Limited clinical evaluation.	Biswal et al., 2017


	Hyperkalaemia (≥6 mmol/L)*	Creatinine ≥220 μmol/L	≥30% increase in creatinine

Number with adverse biochemical values†	128/6373 (2.0%)	177/6520 (2.7%)	877/6520 (13.5%)

Number discontinuing AA‡	68/128 (53.1%)	76/177 (42.9%)	251/877 (28.6%)


Clean-up method	According to reference	Total solvent (mL)	Time (h)	Swelling (%)	Release of oligomers (%)

Soxhlet extraction ethylacetate	Smedes and Booij (2012)	400	100	92	2.5

Extraction ethylacetate	Shahpoury and Hageman (2013)	400	48	76	2.4

Extraction n-hexane/acetone (3:1)	Schäfer et al.(2010)	800	96	124	2.5

ASE n-hexane/acetone (1:1)	This study	169	1.2	42	2.2

Clean-up method

Soxhlet extraction ethylacetate

Extraction ethylacetate

Extraction n-hexane/acetone (3:1)

ASE n-hexane/acetone (1:1)

According to reference	Total solvent (mL)	Time (h)	Swelling (%)	Release of oligomers (%)

Smedes and Booij (2012)	400	100	92	2.5

Shahpoury and Hageman (2013)	400	48	76	2.4

Schäfer et al.(2010)	800	96	124	2.5

This study	169	1.2	42	2.2


	Recurrence	No recurrence	p value

n	9		187

Mean age (SD)	55.3	(13.9)	55.9	(12.1)	n.s.

Stagea

I	2		87

IIA or B	4		96		<0.01

IIIA or B	3		4

Histology

Ductal	7		161

Lobular	2		11		n.s.

Others	0		15

High nuclear grade	11%	(1/9)	4%	(7/181)	n.s.

High histological grade	22%	(2/9)	4%	(6/141)	n.s.

ERb	100%	(9/9)	100%	(187/187)	n.s.

PRb	67%	(6/9)	78%	(145/187)	n.s.

Mean Ki67 (%) (SD)	37.9	(21.7)	24.1	(18.5)	<0.05

(Neo-) adjuvant therapy

Endocrine + chemotherapy	9		52

Endocrine therapy only	0		127

Chemotherapy only	0		1

None	0		7

	Recurrence	No recurrence	p value

n	9		187

Mean age (SD)	55.3	(13.9)	55.9	(12.1)	n.s.

Stagea

I	2		87

IIA or B	4		96		<0.01

IIIA or B	3		4

Histology

Duc	7		161

tal

Lobular	2		11		n.s.

Others	0		15

High nuclear grade	11%	(1/9)	4%	(7/181)	n.s.

High histological grade	22%	(2/9)	4%	(6/141)	n.s.

ERb	100%	(9/9)	100%	(187/187)	n.s.

PRb	67%	(6/9)	78%	(145/187)	n.s.

Mean Ki67 (%) (SD)	37.9	(21.7)	24.1	(18.5)	<0.05

(Neo-) adjuvant therapy

Endocrine + chemotherapy	9		52

Endocrine therapy only	0		127

Chemotherapy only	0		1

None	0		7


Category	Value

Total patients enrolled	80

Number of groups	15

Number of geographic areas with groups	9

Average number of patients per group	5.3

Female, number (%)	51 (63.8%)

Age at enrollment (years), median (IQR)	44 (36–51)

CD4 count at enrollment (cells/mL), median (IQR)	509 (382–670)

Months on ART prior to enrollment, median (IQR)	45.2 (22.4–65.6)

Category	Value

Number of groups	15

Number of geographic areas with groups	9

Average number of patients per group	5.3

Female, number (%)	51 (63.8%)

Age at enrollment (years), median (IQR)	44 (36–51)

CD4 count at enrollment (cells/mL), median (IQR)	509 (382–670)

Months on ART prior to enrollment, median (IQR)	45.2 (22.4–65.6)


	Group 1 (dose escalation)	Group 2 (1.35 × 105 PfSPZ)	Group 3 (2.7 × 105 PfSPZ)	Group 4 (2.7 × 105 PfSPZ)	Total PfSPZ vaccine	NS controls

Number of volunteers	3	20	20	6	49	8

Total number of injections	9	99	100	29	237	40

Number of local AEs	0	0	0	0	0	0

Numbers of systemic AEs (% of total immunizations)

All	1 (11%)	10 (10.1%)	6 (6%)	0	17 (7.2%)	2 (5.0%)

Headache*	1 (11%)	7 (7%)†	2 (2%)	0	10 (4.2%)	1 (2.5%)

Abdominal pain	0	2 (2%)	1 (1%)	0	3 (1.3%)	0

Chills	0	0	1 (1%)	0	1 (0.4%)	0

Fever	0	0	2 (2%)	0	2 (0.8%)	0

Diarrhea	0	0	0	0	0	1 (2.5%)

Chest pain	0	1 (1%)	0	0	1 (0.4%)	0

Other	0	0	0	0	0	0

Systemic AEs - no. volunteers with ≥ 1 event (% of volunteers)

Any	1 (33%)	7 (35%)	2 (10%)	0	10 (20.4%)	1 (13%)


PhenX family history of MI?	PMRP family history of MI/Angina

Yes	No	Yes	No

N	%	N	%	N	%	N	%

1108	52.8	991	47.2	589	28.1	1510	71.9

Kappa=0.352 (95% CL=0.317, 0.386)


Combined category	Includes	Constructed for wave

Any mood disorder	MDD, Dysthymia	1 and 2

Any anxiety disorder W1	Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD, OCD, PTSD.	1

Any Anxiety disorder W1–2	Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD.	1 and 2

Any anxiety disorder W1–2 excluding specific phobias	Panic disorder, Agoraphobia without a history of panic disorder, Social phobia, GAD.	1 and 2

AUD	Alcohol abuse, Alcohol dependence.	1 and 2

Any mental disorder W1	Any mood disorder, Any anxiety disorder W1, AUD.	1

Any mental disorder W1–2	Any mood disorder, Any anxiety disorder W1–2, AUD.	1 and 2

Any mental disorder W1–2 excluding specific phobias	Any mood disorder, Any anxiety disorder W1–2 excluding specific phobias, AUD.	1 and 2

Categories only presented in Supplementary table

Drug use disorder	Drug abuse, drug dependence.	1

Any substance use disorder	Drug use disorder, AUD.	1

Any disorder W1- supplement	Any mood disorder, Any anxiety disorder W1, Any substance use disorder	1


Parameters	Value

Number of unigenes	68,961

Number of transcripts	134,793

Average unigene length (bp)	1322

Average transcript length (bp)	1600

Unigene N50 (bp)	1721

transcript N50 (bp)	2263

Minimum unigene length (bp)	201

Minimum transcript length (bp)	201

Maximum unigene length (bp)	15,890

Maximum transcript length (bp)	15,890

Parameters

Number of unigenes

Number of transcripts

Average unigene length (bp)

Average transcript length (bp)

Unigene N50 (bp)

transcript N50 (bp)

Minimum unigene length (bp)

Minimum transcript length (bp)

Maximum unigene length (bp)

Maximum transcript length (bp)


Characteristic	Univariate analysis

HR (95% CI)	P value

Age (≤ 40 vs. > 40 years)	1.038 (0.614–1.752)	0.890

T stage (pT0–T1 vs. pT2-T4)	1.393 (0.897–2.164)	0.140

Family history of breast cancer (yes vs. no)	0.771 (0.386–1.543)	0.463

Axillary lymph node status (negative vs. positive)	2.507 (1.615–3.890)	< 0.001

TNM stage (0-I vs. II-III)	2.063 (1.221–3.485)	0.007

Pathological type (invasive ductal carcinoma vs. others)	0.874 (0.450–1.695)	0.689

Vascular invasion (yes vs. no)	2.486 (1.497–4.126)	< 0.001

ATG5 rs473543 genotype (AA/GA vs. GG)	1.717 (1.036–2.847)	0.036


A	B	C	D	E	F	G	H	I	J	K

1	24	LD	Good	86	48 + 8	Screw track infection	12	90/85	Excellent	10–40

2	24	RS	Good	36	13 + 7	–	12	89/78	Excellent	15–50

3	24	Repair	Good	27	9 + 5	Superficial infection	6	91/80	Excellent	10–30

4	12	RS	Good	60	13 + 6	–	6	91/81	Good	5–20

5	24	RS	Good	97	8 + 7	–	9	89/80	Good	15–60

6	12	RS	Fair	62	44 + 5	Superficial infection	6	90/78	Good	5–30

7	24	Repair	Good	26	8 + 6	–	6	88/75	Excellent	15–50

8	24	RS	Good	28	10 + 9	–	6	87/77	Excellent	10–40

9	36	ALT	Good	83	36 + 7	–	12	94/77	Excellent	5–30

10	24	Repair	Good	32	22 + 8	–	6	90/80	Good	10–40

11	24	Repair	Good	27	21 + 8	Screw track infection	6	91/79	Good	20–50

12	12	Repair	Good	47	9 + 6	–	12	95/81	Good	10–30

13	12	Repair	Good	31	13 + 9	–	6	90/80	Good	10–40

14	24	LD	Good	54	26 + 7	–	6	93/80	Excellent	10–50

15	24	RS	Good	97	11 + 9	–	6	87/84	Good	10–40

16	12	Repair	Good	51	27 + 11	–	12	90/75	Good	10–20

A	B	C	D	E

1	24	LD	Good	86

2	24	RS	Good	36

3	24	Repair	Good	27

4	12	RS	Good	60

5	24	RS	Good	97

6	12	RS	Fair	62

7	24	Repair	Good	26

8	24	RS	Good	28

9	36	ALT	Good	83

10	24	Repair	Good	32

11	24	Repair	Good	27

12	12	Repair	Good	47

13	12	Repair	Good	31

14	24	LD	Good	54

15	24	RS	Good	97

16	12	Repair	Good	51


Household assets	Yes	No

Electricity	120 (32%)	261 (69%)

Running water (tap)	39 (10%)	342 (90%)

Water closet toilet	65 (17%)	316 (83%)

Solar power	57 (15%)	324 (85%)


Patient characteristics

Mean age	Years 40.3	SD 16.4	Min 27.0	Max 55.0

Median length of stay	Years 5.5	SD 6.8	Min 0.5 yrs	Max 33.5 yrs

Ward location

Low secure hostel	6 [12%]

Low secure rehabilitation ward	11 [20%]

Medium security rehabilitation	15 [29%]

Medium security sub-acute	14 [27%]

High secure [long stay]	6 [12%]

Community leave status

Community leave	36 [70%]

No community Leave	16 [30%]

Primary Diagnosis

Schizophrenia/ Schizoaffective disorder	52 [100%]

Patient characteristics

Mean age

Median length of stay

Ward location

Low secure hostel

Low secure rehabilitation ward

Medium security rehabilitation

Medium security sub-acute

High secure [long stay]

Community leave status

Community leave

No community Leave

Primary Diagnosis

Schizophrenia/ Schizoaffective disorder


	5 Fr Catheters (n = 49)	7 Fr Catheters (n = 48)	P

Total discomfort#1	3.2 ± 0.2	3.9 ± 0.2	0.018

Difficulty with eating#1	2.2 ± 0.1	2.7 ± 0.2	0.079

Nasal hemorrhage#2	1 (2)	0 (0)	0.320

Sore throat#2	6 (12)	9 (18)	0.376

Nausea#2	0 (0)	1 (2)	0.310

Caught on a nearby object#2	1 (2)	1 (2)	0.988

Other adverse events#2	10 (20)	10 (20)	0.481

	5 Fr Catheters (n = 49)	7 Fr Catheters (n = 48)	P

Caught on a nearby object#2	1 (2)	1 (2)	0.988

Other adverse events#2	10 (20)	10 (20)	0.481


Error number:Check the appropriate boxes	Physician assessment number: 1 or 2

Potential severity according to the Medication Error Index (3)

No consequences for the patient

An error avoided that would not cause patient harm

An error avoided that would require monitoring to confirm that it did not result in patient harm

Temporary damage	Potential clinical consequences	Potential hospitalisation and treatment*

An error avoided that could have contributed to temporary harm to the patient, requiring intervention	Acute renal failure	Hospitalisation

	Cardiac toxicity	Prolongation of the initial hospitalisation

	Skin toxicity	New hospitalisation

An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation	Neutropenia	Type of ward

	Thrombopenia	Standard hospitalisation unit

	Anemia	Day-care unit

	Febrile neutropenia	Intensive care unit

	Neurotoxicity	Number of additional days of hospitalisation

Permanent damage	Hepatic cytolysis	Treatments

An error avoided that could have contributed to permanent patient harm	Hepatic cholestasis	Platelet transfusions

Compromised vital prognosis	Diarrhea	Erythrocyte transfusions

An error avoided that could have required intervention necessary to sustain life	Vomiting	Granulocyte Colony Stimulating Factor

Patient death	Other:	Parenteral nutrition

		Other:

An error avoided that could have contributed to the patient's death

Error number:Check the appropriate boxes	Physician assessment number: 1 or 2

Potential severity according to the Medication Error Index (3)

No consequences for the patient

An error avoided that would not cause patient harm

An error avoided that would require monitoring to confirm that it did not result in patient harm

	Skin toxicity	New hospitalisation

An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation	Neutropenia	Type of ward

	Thrombopenia	Standard hospitalisation unit

	Anemia	Day-care unit

	Febrile neutropenia	Intensive care unit

	Neurotoxicity	Number of additional days of hospitalisation

Permanent damage	Hepatic cytolysis	Treatments

An error avoided that could have contributed to permanent patient harm	Hepatic cholestasis	Platelet transfusions

Compromised vital prognosis	Diarrhea	Erythrocyte transfusions

An error avoided that could have required intervention necessary to sustain life	Vomiting	Granulocyte Colony Stimulating Factor

Patient death	Other:	Parenteral nutrition

		Other:

An error avoided that could have contributed to the patient's death


Characteristics	Younger men without CAD (n = 25)	Older men without CAD (n = 25)	Younger men with CAD (n = 19)	Older men with CAD (n = 19)	P-value	Adjusted P-valuea

Age (years)	53.6 ± 1.4	72.6 ± 1.5	54.3 ± 1.9	73.4 ± 1.9	<0.001	-

BMI (kg/m2)	28.1 ± 1.1	27.0 ± 0.7	29.0 ± 1.2	26.3 ± 0.5	0.21	0.33

Waist circumference (cm)	100.4 ± 3.2	99.9 ± 1.7	102.2 ± 3.3	100.6 ± 1.7	0.94	0.81


Personal history of hiatal hernia	Family history of hiatal hernia		EA	GCA	DGA

Controls	Cases	OR (95% CI)a	Pa	Cases	OR (95% CI)a	Pa	Cases	OR (95% CI)a	Pa

No	No	1117	93	1.00 (ref)		129	1.00 (ref)		249	1.00 (ref)

No	Yes	68	6	1.26 (0.52-3.08)	0.61	13	1.89 (0.99-3.61)	0.056	8	0.89 (0.40-1.97)	0.77


 	GG n = 146	GC/CC n = 64	p value

Infection type

Gram-negative	62%	81%	0.0062

Gram-positive	83%	83%	1.0000

Fungal	52%	58%	0.4565

Viral	18%	17%	1.0000

Parasitic	0%	0%

Other	1%	3%


Stem cell source	Benefits	Drawbacks

	Donor	Recipient	Donor	Recipient

BM		Lower risk of GvHD	More invasive HSC collection

PBSC	No general anesthesia for collection; less discomfort and pain	Faster hematopoietic engraftment and immune reconstitution; enhanced GvL effect		Higher risk of GvHD

CB	Non-invasive	Lower risks of GvHD and relapse; rapid availability; increased level of HLA-disparity tolerated		Lower number of HSCs; slower immune reconstitution

Benefits	Drawbacks

Donor	Recipient	Donor	Recipient

	Lower risk of GvHD	More invasive HSC collection

No general anesthesia for collection; less discomfort and pain	Faster hematopoietic engraftment and immune reconstitution; enhanced GvL effect		Higher risk of GvHD

Non-invasive	Lower risks of GvHD and relapse; rapid availability; increased level of HLA-disparity tolerated		Lower number of HSCs; slower immune reconstitution


Characteristic	Unit	Recommended values (Santos and Borem, 2013)	CTC20	CTC175-A

Fiber	% sugarcane	10–13	10.72	10.41

Starch	mg/kg	<1,000	875	948

Brix	% juice	>14	21.02	20.84

Dextran	mg/kg	<10	<10	<10

RS	% juice	<0.8	0.47	0.47

TRS	% juice	>15	20.54	20

pH	–	4.8–5.8	5.4	5.3

Pol	% juice	>14	19.43	19.26

Purity	% juice	>85	92.44	92.42

Characteristic	Unit	Recommended values (Santos and Borem, 2013)	CTC20	CTC175-A

Purity	% juice	>85	92.44	92.42


CNE	Mt	Zt	Mg	Zg	Trans&Gene	NoTrans&Gene

Hs259	Limbs	+	-	+	-	Yes

Spinal cord	-	+	+	+

Hs327	Hindbrain	+	+	+	+

Forebrain	-	+	+	+

Spinal cord	+	+	+	-	 	Yes

Midbrain	-	+	+	+

Hs382	Forebrain	+	+	+	+

Somites	+	+	+	+

Spinal cord	+	-	+	+

DRG	+	-	+	-	Yes

Eye	-	+	+	+

Notochord	-	+	+	+

Hindbrain	+	-	+	+

Midbrain	+	-	+	+

Hs422	Forebrain	+	+	+	+

Spinal cord	-	+	-	-

Nose	+	-	+	-	Yes

Hindbrain	-	+	-	-

Hs595	Forebrain	+	+	+	+

Midbrain	+	-	+	+

Nose	+	-	+	-	Yes

Hs609	Forebrain	+	-	+	+

Limbs	+	-	+	-	Yes

Hs671	Forebrain	+	+	+	+

Eye	-	+	+	+

Hindbrain	-	+	+	+

DRG	-	+	+	-

Hs672	Forebrain	+	-	+	+

Midbrain	+	+	+	+

Spinal cord	+	-	+	-	Yes

Hs687	Forebrain	+	+	+	+

Spinal cord	+	-	+	-	Yes

Hs774	Hindbrain	+	+	+	+

Limbs	+	+	+	-	 	Yes

Forebrain	-	+	+	+

Eye	-	+	-	+	Yes

Hs1114	Midbrain	+	+	+	+

Hindbrain	+	+	-	+

Spinal cord	+	+	+	+


ISAV Sample(s)	Sequence direction	No. of trimmed reads	Percent of reads identical to Sanger sequence

SCN1a	HE gene forward	50552	82.4

	HE gene reverse	69684	91.4

	F gene forward	44498	91.9

	F gene reverse	49118	89.2

SCN pool 	HE gene forward	25695	78.3

(SCN2, SCN3, SCN4)	HE gene reverse	68481	92.2

	F gene forward	31230	92.1

	F gene reverse	35799	89.5

OBK1b	HE gene forward	52038	92.4

	HE gene reverse	88172	93.0

	F gene forward	31546	91.4

	F gene reverse	46835	89.7

OBK pool 	HE gene forward	40458	92.1

(OBK2, OBK3, OBK4)	HE gene reverse	51772	92.8

	F gene forward	45909	91.9

	F gene reverse	44498	91.9


Treatment	Total cells	Eosinophils	Monocytes	Lymphocytes	Neutrophils

PBS	240 ± 38§	3 ± 1§	201 ± 18	8 ± 5§	10 ± 7

Dpt+Vit A 50	612 ± 36	293 ± 28	198 ± 24	86 ± 15	34 ± 8

Dpt+Vit A 500	624 ± 59	312 ± 29	199 ± 22	82 ± 12	29 ± 7

Dpt+Vit A 2500	428 ± 46	46 ± 35*	284 ± 34	79 ± 11	19 ± 7


Reporting criteria	CDE Programme

Where was the intervention delivered and why?	Primary care settings (GP surgeries) and community settings with a single lay educator (or with the use of interpreters when necessary

What behavioural change theory has intervention been based on (if any)?	Social learning theory

What behaviour change techniques were used by people delivering the intervention (if any)*?	1, 2, 4, 6, 8, 10, 19, 22, 24

A description of the activities and material provided in each workshop and their intended outcomes?	Material: information on weight management, choosing healthier foods, meal planning, physical exercise, checking and improving metabolic control and preventing complications.

Activities: participants taking each other’s blood pressure, BMI calculations, understanding sugar and salt content in foods, Eat-well plate, food maps, guided imagery, ‘freethink’.

Intended outcomes: desirable body weight, learn to shop for food, increase physical activity, take medication properly and regularly, recognise early symptoms of condition, regularly attend clinics, improved symptom control, reduced BMI, improved quality of life and knowledge of condition, reduced level of prescribing, slower disease progression, management of condition, carry out normal roles and activities, and manage emotional impact of illness.

What support (if any) was provided to individuals outside of workshops?	No contact outside of workshops.

Was a manual or protocol used to deliver the intervention and are there details on how it can be accessed?	Manual is available to lay educators, however, not used during intervention. Can be accessed via permission from Health Exchange.

How were individuals referred to the programme?	Patients suffering from diabetes mellitus, coronary heart disease and/or chronic kidney disease were invited to attend the programme. Patients referred to the programme by general practitioners, practice nurses or practice staff. Practices citing a lack of time asked CDEs to contact patients on chronic disease registers directly by phone or postal mail.

Were any cultural or structural adaptations used?	Delivery in various languages, cultural adaptation of educational material, application of visual aids and demonstrations, understandable terminology, emotional well-being, culturally sensitive approach to delivery, recruitment of lay personnel, delivery in community locations, and religious/cultural acknowledgement.


	Trial I	Trial II

	Filtered music	Headphones only condition	Filtered music	Unfiltered music

	Mean age (SD)b	Mean age (SD)b	Mean age (SD)b	Mean age (SD)b

Met at least partial criteria on ADI-Ra

Male	58.24 (10.14), n = 25	49.46 (10.96), n = 23	54.89 (14.83), n = 44	56.20 (9.36), n = 27

	Trial I	Trial II

	Filtered music	Headphones only condition	Filtered music	Unfiltered music

	Mean age (SD)b	Mean age (SD)b	Mean age (SD)b	Mean age (SD)b

Femalec	48.67 (11.99), n = 11	61.00 (7.91), n = 5	44 (20.66), n = 6	60.33 (9.29), n = 5

Total	55.37 (11.42), n = 36	52.67 (11.30), n = 28	53.33 (15.95), n = 50	56.74 (9.25), n = 32


	Low utilization	Intermediate utilization	High utilization

	Median	IQR	Median	IQR	Median	IQR

Volume measures (n)

 Annual PICU admissions	1582	(977, 2602)	2283	(1678, 2657)	1614	(1475, 2241)NS

 Annual cardiac surgical volume	184	(116, 340)	233	(145, 314)	224	(180, 249)NS

PICU severity of illness measures (%)

 Mechanical ventilation admits	36.8%	(26.9, 53.4)	43.9%	(37.5, 46.9)	36.9%	(31.3, 45.2)NS

 APR DRG SOI category 3	32.4%	(28.7, 34.3)	31.7%	(29.0, 33.7)	30.5%	(29.7, 34.0)NS

 APR DRG SOI category 4	20.3%	(15.2, 22.2)	24.2%	(17.4, 27.2)	20.7%	(19.1, 21.9)NS


Measured variables	Pretest(n = 17)	Posttest(n = 17)	Test power	Effect size

Mean ± SD	Mean ± SD

SMMI	8.97 ± 1.69	10.52 ± 2.35	0.95	0.7529

Physical fitness

 Standing on one foot (seconds)	3.30 ± 7.19	7.36 ± 12.32	0.95	0.4023

 Shoulder–arm flexibility (centimeters)	−37.50 ± 16.33	− 28.56 ± 13.94	0.95	0.5884

 8-ft up and go test (seconds)	36.2 ± 24.57	22.00 ± 17.25	0.95	−0.7091

 Grip strength (kilograms)	11.19 ± 7.36	14.45 ± 7.48	0.95	0.4399

 Five repeated sit-to-stand tests (seconds)	42.42 ± 22.98	30.58 ± 15.31	0.95	−0.6063

Measured variables	Pretest(n = 17)	Posttest(n = 17)	Test power	Effect size

Mean ± SD	Mean ± SD

Five repeated sit-to-stand tests (seconds)	42.42 ± 22.98	30.58 ± 15.31	0.95	−0.6063


Score of the reader	Sensitivity	Specificity

CXR on all suspects (n = 998)

a) Highly consistent for TB	68 (64–72)	90 (87–93)

b) Consistent for TB	23 (19–26)	77 (73–80)

c) Pathology, but no TB	2 (0–3)	96 (94–98)

"TB" (a+b)	91 (88–93)	67 (62–71)

"any pathology" (a+b+c)	92 (90–94)	63 (58–67)

CXR on suspects excluding those who were ZN positive (n = 657)

a) Highly consistent for TB	48 (42–55)	90 (87–93)

b) Consistent for TB	31 (25–37)	77 (73–81)

c) Pathology but no TB	3 (1–5)	96 (95–98)

"TB" (a+b)	80 (74–85)	67 (62–71)

The entire diagnostic process (n = 998)

ZN followed by CXR	93 (91–95)	62 (57–67)

CXR followed by ZN	89 (86–91)	97(84–90)


	Non-survey days	Survey days	Adjusted comparisona

Number of consultations per day					Difference	95 % CI	p

Mean (SD)	11.9	(7.3)	14.1	(10.3)	2.03	1.20- 2.86	<0.001

Median (IQR)	11	(7–16)	12	(8–17)

Mis		%			OR	9	p


Honey source	Samples	Parameters

pH	Moisture (%)	EC (mS/cm)	TDS (ppm)	Colour (nm)	ABS450 (mAU,50w/v)

Apis		4.46 ± 0.0	11.870 ±	0.163 ± 0.0153		1.986 ± 0.0


Scenario	Deaths per 1,000 live births in 2010 (95% CI)	Annualized rate of decline, 1990–2010 (95% CI)

Currently estimated values	111 (108, 115)	2.2% (2.0–2.4%)

Counterfactual at 2005 coverage levels	119 (114, 123)	1.9% (1.7–2.1%)

Counterfactual at 2000 coverage levels	124 (118, 129)	1.7% (1.5–1.9%)


GO-ID	Term	Categorya	FDRb	P-Value	#Test	#Ref	#notAnnot Test	#notAnnot Ref

GO:0005506	iron ion binding	F	3.99E-07	9.40E-11	17	153	115	9554

GO:0055114	oxidation-reduction process	P	1.09E-06	6.16E-10	31	636	101	9071

GO:0016491	oxidoreductase activity	F	1.09E-06	7.68E-10	31	642	101	9065

GO:0004497	monooxygenase activity	F	6.16E-06	5.87E-09	13	106	119	9601

GO:0020037	heme binding	F	6.16E-06	8.61E-09	15	157	117	9550

GO:0046906	tetrapyrrole binding	F	6.16E-06	9.33E-09	15	158	117	9549

GO:0044710	single-organism metabolic process	P	6.16E-06	1.02E-08	52	1747	80	7960

GO:0016705	oxidoreductase activity, acting on paired donors, with incorporation	F					117	9534

	or reduction of molecular oxygen		1.53E-05	2.88E-08	15	173

GO:0003824	catalytic activity	F	5.33E-03	1.13E-05	75	3644	57	6063

GO-ID	Term	Categorya	FDRb	P-Value	#Test	#Ref	#notAnnot Test	#notAnnot Ref

GO:0055114	oxidation-reduction process	P	1.09E-06	6.16E-10	31	636	101	9071

GO:0016491	oxidoreductase activity	F	1.09E-06	7.68E-10	31	642	101	9065

GO:0004497	monooxygenase activity	F	6.16E-06	5.87E-09	13	106	119	9601

GO:0020037	heme binding	F	6.16E-06	8.61E-09	15	157	117	9550

GO:0046906	tetrapyrrole binding	F	6.16E-06	9.33E-09	15	158	117	9549

GO:0044710	single-organism metabolic process	P	6.16E-06	1.02E-08	52	1747	80	7960

GO:0016705	oxidoreductase activity, acting on paired donors, with incorporation	F					117	9534

	or reduction of molecular oxygen		1.53E-05	2.88E-08	15	173

GO:0003824	catalytic activity	F	5.33E-03	1.13E-05	75	3644	57	6063


Gingival index	Number of patients

0	23

1	55

2	16

3	14

Total	108

Gingival index	Number of patients

2	16

3	14

Total	108


Peptide	Sequence	Portal vein (nM/h)	Jugular vein (nM/h)	CL Rat (mL/min/Kg)	Liver first pass effect (%)

(4)	[Abu-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	1839	1656	41	11

(5)	[Ala-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	449	104	70	77

Sequence	Portal vein (nM/h)	Jugular vein (nM/h)	CL Rat (mL/min/Kg)	Liver first pass effect (%)

[Abu-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	1839	1656	41	11

[Ala-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	449	104	70	77


Group	0 month	6 months	12 months	18 months	24 months	30 months	36 months


Postal	Electronic

Monetary or non-monetary incentives	Non-monetary incentives

Teaser on the envelope	Personalised questionnaires

Pre-notification	Include pictures

Follow-up with another copy included	Not including ‘survey’ in subject line

Handwritten addresses	Male signature

University sponsorship	White background

Use recorded delivery	Short questionnaire

Include return envelope	Offer of results

Avoid sensitive questions	Statement that others have responded


	Control	iStroke	P

Time, minutes, mean ± SD	14.6 ± 7.4	7.3 ± 5.2	0.010

Total missed contraindication counts, n (%a)	23 (42.6)	7 (13.0)	0.001

Missed contraindication counts per physician

 Mean ± SD	1.9 ± 0.7	0.6 ± 1.0	0.001

 Median	2.0	0	0.002

Missed contraindication counts per item

 Mean ± SD	3.8 ± 2.5	1.2 ± 1.5	0.047

 Median	3.5	1.0	0.027


Mutation	Score	Confidence	Domain	Prediction

R61W	0.773	Sensitivity: 0.76	EGF-like 1	Possibly damaging

Especificity: 0.86

R75P	0.884	Sensitivity: 0.71	EGF-like 1	Possibly damaging

Especificity: 0.89

D80G	0.694	Sensitivity: 0.78	EGF-like 2	Possibly damaging

Especificity: 0.85

R213K	0.171	Sensitivity: 0.89	EGF-like 5	Benign

Especificity: 0.72

Mutation	Score	Confidence	Domain	Prediction

R61W	0.773	Especificity: 0.86	EGF-like 1	Possibly damaging

R75P	0.884	Sensitivity: 0.71	EGF-like 1	Possibly damaging

Especificity: 0.89

D80G	0.694	Sensitivity: 0.78	EGF-like 2	Possibly damaging

Especificity: 0.85

R213K	0.171	Sensitivity: 0.89	EGF-like 5	Benign

Especificity: 0.72


Source	Df	F

Species	8	24.6***

Water Level	1	13.3***

Species* Water	8	1.2


Bacterial strains/Plasmids	Characteristic	Source/Reference

Brucella ovis

PA	virulent strain, natural NalR	CITA collection

BoΔwadA	PA in frame deletion mutant in wadA Δ58-679	This work

BoΔwadB	PA in frame deletion mutant in wadB Δ49-195	This work

BoΔwadC	PA in frame deletion mutant in wadC Δ17-306	This work

BoPA-Gm	challenge strain, PA GmR	UN collection

Brucella melitensis

Rev 1	reference vaccine	CITA collection

E. coli

S17-1 λpir	mating strain with plasmid RP4 inserted into the chromosome	Simon et al. [[19]]

TOP10 F’	F−lacIq Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74 recA1alaD139 endA1 nupG	Invitrogen

Plasmids

pCR2.1	cloning vector	Invitrogen

pJQK	derivated of pJQ200KS+; KmR, GmS	Scupham and Triplett [[20]]

pYRI-12	913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele, generated by PCR and cloned into pCR2.1	This work

pYRI-13	BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK	This work

pYRI-1	570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele, generated by PCR and cloned into pCR2.1	Gil-Ramírez et al. [[7]]

pYRI-2	BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK	Gil-Ramírez et al. [[7]]

pYRI-14	934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele, generated by PCR and cloned into pCR2.1	This work

pYRI-15	BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK	This work

Bacterial strains/Plasmids	Characteristic

Brucella ovis

PA	virulent strain, natural NalR

BoΔwadA	PA in frame deletion mutant in wadA Δ58-679

BoΔwadB	PA in frame deletion mutant in wadB Δ49-195

BoΔwadC	PA in frame deletion mutant in wadC Δ17-306

BoPA-Gm	challenge strain, PA GmR

Brucella melitensis

Rev 1	reference vaccine

E. coli

S17-1 λpir	mating strain with plasmid RP4 inserted into the chromosome

TOP10 F’	F−lacIq Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74 recA1alaD139 endA1 nupG

Plasmids

pCR2.1	cloning vector

pJQK	derivated of pJQ200KS+; KmR, GmS

pYRI-12	913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele, generated by PCR and cloned into pCR2.1

pYRI-13	BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK

pYRI-1	570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele, generated by PCR and cloned into pCR2.1

pYRI-2	BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK

pYRI-14	934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele, generated by PCR and cloned into pCR2.1

pYRI-15	BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK

Source/Reference

CITA collection

This work

This work

This work

UN collection

CITA collection

Simon et al. [[19]]

Invitrogen

Invitrogen

Scupham and Triplett [[20]]

This work

This work

Gil-Ramírez et al. [[7]]

Gil-Ramírez et al. [[7]]

This work

This work


Age	P0–P1a	P10	P21

Dnaaf1m4Bei	Observedb	Expected	Observedc	Expected	Observedd	Expected

 Wild-type	29	20.5	21	17.5	12	8.25

 Heterozygote	39	41	43	35	21	16.5

 Homozygote	14	20.5	6	17.5	0	8.25

Laterality defect	8 (57.1%)		2 (33.3%)		N/Ae

 Situs inversus	3		0

 Heterotaxy	5		2

Lrrc48m6Bei	Observed	Expected	Observed	Expected	Observed	Expected

 Wild-type	21	18	24	19.75	22	17.75

 Heterozygote	33	36	36	39.5	31	35.5

 Homozygote	18	18	19	19.75	18	17.75

Laterality defect	2 (11.1%)		1 (5.3%)		N/Ae

 Situs inversus	2		0

 Heterotaxy	0		1

Age	P0–P1a	P10	P21

Dnaaf1m4Bei	Observedb	Expected	Observedc	Expected	Observedd	Expected

Wild-type	29	20.5	21	17.5	12	8.25

Heterozygote	39	41	43	35	21	16.5

Homozygote	14	20.5	6	17.5	0	8.25

Laterality defect	8 (57.1%)		2 (33.3%)		N/Ae

Situs inversus	3		0

Heterotaxy	5		2

Lrrc48m6Bei	Observed	Expected	Observed	Expected	Observed	Expected

Wi	2	18	2	19.7	22	17.7

ld-type	1		4	5		5

Heterozygote	33	36	36	39.5	31	35.5

Homozygote	18	18	19	19.75	18	17.75

Laterality defect	2 (11.1%)		1 (5.3%)		N/Ae

Situs inversus	2		0

Heterotaxy	0		1


Cell type	Stimulation	Type of HA binding	HA receptor	Reference

Monocyte (human)	TNFα, LPS, IL-1, IFN-γ	Inducible	CD44	(59–61)

Alveolar macrophages (human, rodents)	None	Constitutive	CD44	(17, 46 –48, 50)

Peritoneal macrophage (mouse)	LPS with IFNγ, or IL-4	Inducible	CD44	(62)

Bone marrow-derived macrophages (mouse)	LPS with IFNγ, TNFα, or IL-4	Inducible	CD44	(62)

Monocyte-derived DC (human)	CD40L expressing fibroblasts	Inducible	CD44	(63)

B cells (human, mouse)	PMA, IL-5, LPS	Inducible, a subset binds	CD44	(64 –67)

T cells (mouse)	PMA/ionomycin, CD3 antibodies, specific antigen, or superantigen	Inducible, often a subset binds	CD44	(54, 55, 68)

CD4+ CD25+ T regulatory cells (human and mouse)	CD3 +/− CD28 activation	Inducible, a subset binds	CD44	(69, 70)

Neutrophil (mouse)	LPS induced liver inflammation in vivo	Binding to SHAP modified HA	CD44, not RHAMM	(71)

NK cells (mouse)	IL-2, IL-15	Inducible, a subset binds	CD44	(72)

Platelets (mouse)	None	Constitutive	CD44	(73)

Cell type	Stimulation	Type of HA binding	HA receptor	Reference

B cells (human, mouse)	PMA, IL-5, LPS	Inducible, a subset binds	CD44	(64 –67)

T cells (mouse)	PMA/ionomycin, CD3 antibodies, specific antigen, or superantigen	Inducible, often a subset binds	CD44	(54, 55, 68)

CD4+ CD25+ T regulatory cells (human and mouse)	CD3 +/− CD28 activation	Inducible, a subset binds	CD44	(69, 70)

Neutrophil (mouse)	LPS induced liver inflammation in vivo	Binding to SHAP modified HA	CD44, not RHAMM	(71)

NK cells (mouse)	IL-2, IL-15	Inducible, a subset binds	CD44	(72)

Platelets (mouse)	None	Constitutive	CD44	(73)


Compound	Elution time (min)	Fraction theoretically contained in

Phenylalanine	5.964 ± 0.003	B

Caffeic acid	13.471 ± 0.170	C

Coumaric acid	15.941 ± 0.208	D

Vanillin	16.187 ± 0.065	D

Cinnamic acid	23.595 ± 0.155	E

Capsaicin	32.801 ± 0.053	G

Compound	Elution time (min)	Fraction theoretically contained in

Caffeic acid	13.471 ± 0.170	C

Coumaric acid	15.941 ± 0.208	D

Vanillin	16.187 ± 0.065	D

Cinnamic acid	23.595 ± 0.155	E

Capsaicin	32.801 ± 0.053	G


Group Variables 	With iron deficiency	Without iron deficiency	P-value

Type of febrile seizure 	Simple	12(37.5%)	20(62.5%)	0.04

Complex 	12(66.7%)	6(33.3%)


Characteristics of the Patients at Baseline	Total population (n = 257)	SR-group (n = 148)	AF-group (n = 109)	p Value

Age — yr	80.8 ± 6.0	80.6 ± 6.0	80.9 ± 6.0	0.736


Strain	Gene name	Protein name	Metabolic function	Fold change

P5	TPI1	Triosephosphateisomerase	Glycolisis	27.28

AHP1	Peroxiredoxin type-2	Oxidative stress	20.07

PDC1	Pyruvate DeCarboxylase	Glycolisis, Glucose fermentation	13.95

TSA1	Thioredoxin peroxidase	Oxidative stress	5.28

CDC19	Pyruvatekinase	Glycolisis, Glucose fermentation	5.16

ENO2	Enolase II, phosphopyruvatehydratase	Glycolisis	3.28

FBA1	Fructose 1,6-bisphosphate aldolase	Glycolisis	2.15

P24	RPL31A	Ribosomal Protein of the Large subunit	Structural constituent of ribosome	17.65

TDH1	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	7.11

TEF1	Translational elongation factor EF-1 alpha	Translation	5.12

TDH3	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	4.76

GPM1	Glycerate phosphomutase	Glycolisis	3.53

ENO2	Enolase II, phosphopyruvatehydratase	Glycolisis	-4.09

P5	FBA1	Fructose 1,6-bisphosphate aldolase	Glycolisis	2.15

P24	RPL31A	Ribosomal Protein of the Large subunit	Structural constituent of ribosome	17.65

TDH1	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	7.11

TEF1	Translational elongation factor EF-1 alpha	Translation	5.12

TDH3	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	4.76

GPM1	Glycerate phosphomutase	Glycolisis	3.53

ENO2	Enolase II, phosphopyruvatehydratase	Glycolisis	-4.09


Protein	Species	Mitochondrial function	Stimulus driving mitochondrial localization	Reference

NF-κB	Rat, mouse	Suppression of mitochondrial genes	Steady-state conditions	Johnson et al., 2011; Johnson and Perkins, 2012

CREB	Rat, mouse	Activation of mitochondrial genes	Steady-state conditions	Lee et al., 2005; Ryu et al., 2005

MEF-2D	Mouse	Transcriptional Activation of ND6	Steady-state conditions	She et al., 2011

TERT	Human, mouse, Rat	Reverse Transcription of mitochondrial tRNAs,Protection from mtDNA damage	Oxidative stress, steady state conditions	Haendeler et al., 2009; Sharma et al., 2012; Saretzki, 2014

RECQL4	Human, mouse	Restores mtDNA replication, Ensures mtDNA integrity	Steady-state conditions	De et al., 2012; Gupta et al., 2014; Wang et al., 2014; Lu et al., 2016

STAT3	Mouse, human	Modulation ETC through direct binding to respiratory complexes	Steady-state conditionsActivated Ras	Gough et al., 2009; Wegrzyn et al., 2009

P53	Rat, mouse, human	Modulation of mitochondrial permeability, apoptosis and necrosis,Promotion of mtDNA accuracy and stability.	Pro-apoptotic signals, oxidative stress, hypoxia, ultraviolet irradiation	Jiang et al., 2006; Marchenko et al., 2007; Bakhanashvili et al., 2008; Vaseva et al., 2012

IRF3	Human	Apoptosis induction by mitochondrial recruitment of BAX	RNA virus infection	Chattopadhyay et al., 2010

STAT1	Mouse, Rat	ND	Steady-state conditions	Boengler et al., 2010

HIF-1α	Human	ND	Hypoxia	Briston et al., 2011

Protein	Species	Mitochondrial function	Stimulus driving mitochondrial localization	Reference

P53	Rat, mouse, human	Modulation of mitochondrial permeability, apoptosis and necrosis,Promotion of mtDNA accuracy and stability.	Pro-apoptotic signals, oxidative stress, hypoxia, ultraviolet irradiation	Jiang et al., 2006; Marchenko et al., 2007; Bakhanashvili et al., 2008; Vaseva et al., 2012

IRF3	Human	Apoptosis induction by mitochondrial recruitment of BAX	RNA virus infection	Chattopadhyay et al., 2010

STAT1	Mouse, Rat	ND	Steady-state conditions	Boengler et al., 2010

HIF-1α	Human	ND	Hypoxia	Briston et al., 2011


Growth and nutritional status of rats

	Body weight gain (g)	Liver weight (g)	Food intake (g/day)	Water intake (ml/day)	Feed efficiency (B.W gain/food intake)

C	16.4 ± 6.67a	6.92 ± 1.42 a	16.03 ± 2.47a	9.33 ± 1.91 ab	1.02

FSO	24.55 ± 9.7 a	8.15 ± 0.83 b	14.94 ± 1.82 ab	10.04 ± 1.53 a	1.64

OSO	20.33 ± 7.81 a	7.54 ± 0.64 ab	13.74 ± 2.41c	9.82 ± 1.5 ab	1.47

MG	25.83 ± 6.64 a	7.27 ± 0.7 a	14.24 ± 2.17 bc	9.07 ± 1.22 b	1.81

Growth and nutritional status of rats

Feed efficiency (B.W gain/food intake)

1.02

1.64

1.47

1.81


Variable	StapleMean (SD)	SutureMean (SD)	t value	P value

Nurse VAS score on day 5	7.57 (1.30)	7.00 (1.10)	2.31	0.023

Nurse VAS score at 6 weeks	8.71 (1.45)	8.55 (1.23)	0.58	0.566

Nurse observer scar width (OSAS) score	1.94 (0.67)	2.26 (1.01)	−1.80	0.075


Size	5 μm	10 μm	15 μm	20 μm

Breakdown voltage	21.25 V	12 V	11.8 V	11.7 V

Dark current	200 pA	60 pA	85 pA	106 pA

Size	5 μm	10 μm	15 μm	20 μm

Break	21.25 		11.8 	1

Size	5 μm	10 μm	15 μm	20 μm

down voltage	V	12 V	V	1.7 V

Dark current	200 pA	60 pA	85 pA	106 pA


Retention indices	Identification %

van den Dool and Kratz	Kovats

Calculated	Adams 2009	Calculated	Adams 2009

1010	1008	1011	1011	δ-3-carene	55.36

933	932	938	939	α-pinene	15.62

1027	1025	1031	1030	sylvestrene	10.69

1479	1480	1481	1481	germacrene D	2.48

1377	1379	1379	1381	β-patchoulene	1.99

988	988	990	990	mircene	1.89


Point	Details

1	Five sites per organ

2	Avoidance of pressure artefacts

3	Elimination of secretions

4	Adequate focus and contrast adjustment

5	High quality recording


	Parent Rating Score

Variable	β1 (95% CI)	β2

Length-for age z-score	−0.416 (−0.928, 0.096)	−0.060

Weight-for-length z-score	−0.747 (−1.483, −0.010)	−0.072

Birth weight (kg)	−0.843 (−1.507, −0.180)	−0.094

Not breastfeeding 3	−0.284 (−0.785, 0.217)	−0.041

Duration of exclusive breastfeeding (age)

3–4 months 4	−0.715 (−1.209, −0.221)	−0.110

5–6 months 4	−0.975 (−1.637, −0.314)	−0.112

Frequent intake of jarred infant food 5	0.419 (−0.122, 0.961)	0.056

Frequent intake of commercial infant cereal 5	1.376 (0.892, 1.860)	0.206

Caregiver passed at least grade 10 6	0.344 (−0.225, 0.913)	0.043

Male infant 7	0.683 (0.238, 1.127)	0.109

Adjusted R2	0.094


Variables	Intervention Group (n = 22)	Comparison Group (n = 22)	p-Value

S	Male, 13 (5	Male


Patient	Sex	Age (years)	Diagnosis	SAPS II score	Pao2/Fio2 ratio (mmHg)	Crs (ml/cmH2O)	LIP (cmH2O)	Pplat (cmH2O)	UIP (cmH2O)

1	F	56	Aspiration	42	121	58	15	22	-

2	M	68	CAP	45	95	25	15	40	-

3	M	40	Aspiration	36	89	122	10	19	-

4	M	51	CAP	25	71	34	5	24	54

5	M	31	Aspiration	34	82	43	-	27	-

6	M	4	Pneumocystis	3	161	5	1		35


			Unstandardized estimates	S.E.	C.R.	P	Standardized estimates

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED HEALTH	-.038	.014	2.825	.005	-.010

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED NEED	-.041	.029	-1.403	.161	-.08

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED VALUE	-.041	.014	-2.875	.004	-.07

PRIVATE HEALTH INSURANCE COVERAGE	<---	SES	.071	.014	5.230	***	.24

PRIVATE HEALTH INSURANCE COVERAGE	<---	GENDER	.006	.027	.225	.822	-.06

PRIVATE HEALTH INSURANCE COVERAGE	<---	AFRICAN AMERICAN	-.175	.037	-4.742	***	-.226

PRIVATE HEALTH INSURANCE COVERAGE	<---	HISPANIC	-.252	.034	-7.332	***	-.18


Inclusion criteria	Exclusion criteria

1. Study design: interventional or observational	1. Studies of exclusively pediatric population (age <18 years)

2. Included population: hospitalized aSAH patients	2. Non-human studies

3. Included intervention: RBC transfusion	3. Duplicates or ‘sub-cohorts’ of previously published cohorts

4. Comparator: a different transfusion threshold or no transfusion

5. Study outcome: any

Inclusion criteria	Exclusion criteria

2. Included population: hospitalized aSAH patients	2. Non-human studies

3. Included intervention: RBC transfusion	3. Duplicates or ‘sub-cohorts’ of previously published cohorts

4. Comparator: a different transfusion threshold or no transfusion

5. Study outcome: any


MIxS-BE term

Carbon dioxidea

Ventilation typea

Organism counta

BE core

 Surface material

 Surface-air contaminant

 Relative air humidity

 Absolute air humidity

 Surface humidity

 Air temperature

 Surface temperature

 Surface moisture pH

 Surface moisture

 Dew point

 Building occupancy type

BE Building properties

 Indoor space (room type)

 Indoor surface

 Filter type

 Heating and cooling system type

 Substructure type

 Building setting

 Light type

BE Sample properties

 Sample size sorting method

 Space typical state

 Typical occupant density

 Occupancy at sampling

 Occupant density at sampling


Dose studied	100 μg	200 μg	400 μg	600 μg	800 μg

1	√		√

2	√			√

3		√			√

4		√	√

3		√			√

4		√	√


Locality	Sample size	CHIKV titer Median copy number (IQR)

w+	w−

w+	w−	Midguts	Salivary glands	Midguts	Salivary glands

Besar Island, Malacca	55	59	6.07 (5.21, 6.93)a*	2.38 (1.63, 4.63)a	7.02 (4.01, 7.80)a	2.16 (1.22, 3.45)a

Tenggol Island, Terengganu	58	60	7.44 (5.20, 8.09)b	2.70 (1.45, 6.36)a	7.83 (6.10, 8.53)b	2.25 (1.44, 4.34)a

Locality	Sample size	CHIKV titer Median copy number (IQR)

w+	w−

w+	w−	Midguts	Salivary glands	Midguts	Salivary glands

Bandar Rinching, Selangor	60	57	7.01 (6.04, 7.69)b	2.93 (1.73, 5.39)a	6.98 (6.02, 7.50)a	2.81 (1.28, 5.50)a


Treatments	Species	Duration	Metabolic disorders	Potential mechanism	Reference

0–250 μmol/l capsaicin	3T3-L1 preadipocytes and adipocytes	24–72 h	Decreased the amount of intracellular triglycerides, GPDH activity	Inhibited the expression of PPARγ, C/EBP-α, and leptin	Hsu et al. [52]

			Induced apoptosis	Induced up-regulation of adiponectin at the protein level

			Inhibited adipogenesis

1 μmol/l capsaicin	3T3-L1 preadipocytes	3–8 days	Prevented the adipogenesis	Increased intracellular calcium	Zhang et al. [53]

0.015% capsaicin	Male C57BL/6 mice	10 weeks	Decreased triglyceride levels	Decreased TRPV-1 expression in adipose tissue	Kang et al. [54]

			Lowered fasting glucose, insulin, and leptin levels	Increased mRNA/protein of adiponectin in the adipose tissue

				Increased PPARα/PGC-1α mRNA in the liver

10 mg/kg body weight capsaicin	Std ddY mice	2 weeks	Lower body weight	Increased oxygen consumption	Ohnuki et al. [55]

			Markedly suppressed body fat accumulation	Stimulated the secretion of adrenalin

			Decreased triglyceride levels

0.3% capsinoids	C57BL/6J mice	8 weeks	Suppressed body weight gain under the HFD	Increased energy expenditure	Saito et al. [57], Ohyama et al. [58]

			Decreased plasma cholesterol level	Activation of fat oxidation in skeletal muscle

			Prevented diet-induced liver steatosis	Activation lipolysis in BAT

				Increased cAMP levels and PKA activity in BAT

0.003%, 0.01%, and 0.03% capsaicin	wild-type and TRPV1−/− mice	16 weeks	Promoted weight loss	Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1α, and PRDM-16 in BAT	Baskaran et al. [59]

			Enhanced the respiratory exchange ratio	Increased the phosphorylation of SIRT-1

			Countered hypercholesterolemia

0.01% capsaicin	wild-type and TRPV1−/− mice	26 weeks	Countered obesity	Promoted SIRT-1 expression	Baskaran et al. [60]

			Browning of WAT	Increased the expression of PGC-1α

				Facilitated PPARγ–PRDM-16 interaction

0.01% capsaicin	wild-type and TRPV1−/− mice	24 weeks	Ameliorated abnormal glucose homeostasis	Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells	Wang et al. [49]

			Increased GLP-1 levels in the plasma and ileum

640 μmol/L, 2 ml/kg capsaicin	Sprague-Dawley rats	15 min	Increased superior mesenteric artery blood flow	Induced a dichotomous pattern of blood flow changes	Leung et al. [68]

			Reduction in hydrogen gas clearance

0.01% capsaicin	C57BL/6J male mice	9 weeks	Reduced weight gain	Modest modulation of the gut microbiota	Shen et al. [69]

			Improved glucose tolerance	Up-regulated the expression of Muc2 and antimicrobial protein gene Reg3g in the intestine

Treatments	Species	Duration	Metabolic disorders	Potential mechanism	Reference

10 mg/kg body weight capsaicin	Std ddY mice	2 weeks	Lower body weight	Increased oxygen consumption	Ohnuki et al. [55]

			Markedly suppressed body fat accumulation	Stimulated the secretion of adrenalin

			Decreased triglyceride levels

0.3% capsinoids	C57BL/6J mice	8 weeks	Suppressed body weight gain under the HFD	Increased energy expenditure	Saito et al. [57], Ohyama et al. [58]

			Decreased plasma cholesterol level	Activation of fat oxidation in skeletal muscle

			Prevented diet-induced liver steatosis	Activation lipolysis in BAT

				Increased cAMP levels and PKA activity in BAT

0.003%, 0.01%, and 0.03% capsaicin	wild-type and TRPV1−/− mice	16 weeks	Promoted weight loss	Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1α, and PRDM-16 in BAT	Baskaran et al. [59]

			Enhanced the respiratory exchange ratio	Increased the phosphorylation of SIRT-1

			Countered hypercholesterolemia

0.01% capsaicin	wild-type and TRPV1−/− mice	26 weeks	Countered obesity	Promoted SIRT-1 expression	Baskaran et al. [60]

			Browning of WAT	Increased the expression of PGC-1α

				Facilitated PPARγ–PRDM-16 interaction

0.01% capsaicin	wild-type and TRPV1−/− mice	24 weeks	Ameliorated abnormal glucose homeostasis	Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells	Wang et al. [49]

			Increased GLP-1 levels in the plasma and ileum

640 μmol/L, 2 ml/kg capsaicin	Sprague-Dawley rats	15 min	Increased superior mesenteric artery blood flow	Induced a dichotomous pattern of blood flow changes	Leung et al. [68]

			Reduction in hydrogen gas clearance

0.01% capsaicin	C57BL/6J male mice	9 weeks	Reduced weight gain	Modest modulation of the gut microbiota	Shen et al. [69]

			Improved glucose tolerance	Up-regulated the expression of Muc2 and antimicrobial protein gene Reg3g in the intestine


Themes	Subtheme	Item

LEADERSHIP/Governance	Systematic Approach	Giving no priority to the discharge planning in heath systemLack of comprehensive plan to develop discharge planning in the ministry of healthLack of patient-centered approach in the health systemLack of systematic and comprehensive approach to the planDisregarding the holistic care in training curriculum

Structure	Lack of referral system and rationing of health services systemLack of structured, systematic and coordinated systemLack of comprehensive benefit packageLack of specific standards, rules, regulations on discharge planning

Management	Low willpower of senior managersPoor monitoring and evaluation systemPoor and inefficient management in heath systemManagers and policy makers’ inaccurate comprehension of discharge planning

Communication	Poor inter and intra sectional contributionLack of defined interaction and communication among medical personnel to provide careWeakness in written supportive policies on discharge planning

Advocacy	Lack of home care system in health systemLack of powerful supportive centers (such as community-based organizations)

Themes	Subtheme	Item

LE	Systematic Approach	Giving no priority to the discharge planning in heath systemLack of comprehensive plan to develop discharge planning in the ministry of healthLack of patient-centered approach in the health systemLack of systematic and comprehensive approach to the planDisregarding the holistic care in training curriculum

Structure	Lack of referral system and rationing of health services systemLack of structured, systematic and coordinated systemLack of comprehensive benefit packageLack of specific standards, rules, regulations on discharge planning

Management	Low willpower of senior managersPoor monitoring and evaluation systemPoor and inefficient management in heath systemManagers and policy makers’ inaccurate comprehension of discharge planning

Communication	Poor inter and intra sectional contributionLack of defined interaction and communication among medical personnel to provide careWeakness in written supportive policies on discharge planning

Advocacy	Lack of home care system in health systemLack of powerful supportive centers (such as community-based organizations)

Themes	Subtheme	Item

ADERSHIP/Governance


	Treatment	DF	F-value	P-value	R-square

Emergence Holes	Depth (D)	4	19.90	<0.001	68.53

Volume (V)	2	83.25	<0.001

Error	113

Air holes	Depth (D)	4	22.51	<0.001	71.60

Volume (V)	2	97.46	<0.001

Error	113

Seed Weight	Depth (D)	4	19.00	<0.001	56.84

Volume (V)	2	36.41	<0.001

Error	113

	Treatment	DF	F-value	P-value	R-square

Emerg	Depth (D)	4	19.90	<0.001	6

Volume		83.25	<0.0


		Mcm2 immunoreactivity

Variable	Categorisation	n analysable	negative (<40%)	positive (≥40%)	pa

Clinico-pathologic data:

Age at diagnosis

	<65 years	47	27	20	1.000

	≥65 years	63	37	26

Gender

	male	72	39	33	0.593

	female	57	34	23

Ann Arbor Stage

	1	15	10	5	0.342

	2	34	15	19

	3	23	14	9

	4	35	22	13

International prognostic index

	0	2	2	0	0.122

	1	48	27	21

	2	21	14	7

	3	20	13	7

	4	14	4	10

Bone marrow involvement

	no	72	39	33	0.414

	yes	35	22	13

Extranodal involvement

	no	40	27	13	0.103

	yes	62	31	31

Bulky disease

	no	62	44	20	0.003

	yes	35	13	22

Serum levels of LDH at diagnosis

	<300 U/l	42	23	19	0.505

	≥300 U/l	41	26	15

		Mcm2 immunoreactivity

Variable	Categorisation	n analysable	negative (<40%)	positive (≥40%)	pa

dal involvement

	no	40	27	13	0.103

	yes	62	31	31

Bulky disease

	no	62	44	20	0.003

	yes	35	13	22

Serum levels of LDH at diagnosis

	<300 U/l	42	23	19	0.505

	≥300 U/l	41	26	15


Fibroblast	PD+/− rotenone (R)	Number of DEGs

MRC-5	PD38 − R to PD38 + R	1

PD42 − R to PD42 + R	2086

PD48 − R to PD48 + R	3527

PD52 − R to PD52 + R	319

HFF	PD22 − R to PD22 + R	1

PD26 − R to PD26 + R	4873

PD30 − R to PD30 + R	8151

PD34 − R to PD34 + R	6424

PD58 − R to PD58 + R	5726

PD74 − R to PD74 + R	60

PD+/− rotenone (R)	Number of DEGs

PD38 − R to PD38 + R	1

PD42 − R to PD42 + R	2086

PD48 − R to PD48 + R	3527

PD52 − R to PD52 + R	319

PD22 − R to PD22 + R	1

PD26 − R to PD26 + R	4873

PD30 − R to PD30 + R	8151

PD34 − R to PD34 + R	6424

PD58 − R to PD58 + R	5726

PD74 − R to PD74 + R	60


Common name	Species	LTA	LTB

Deer mouse	Peromyscus maniculatus	AY251294	AY282503

House mouse	Mus musculus	NM_010735	MMU16984

Rat	Rattus norvegicus	NM_080769	BX883046

Woodchuck	Marmota monax	AF095586	AF095587

Human	Homo sapiens	AY216498	AY216497

Common name	Species	LTA	LTB

Deer mouse	Peromyscus maniculatus	AY251294	AY282503

House mouse	Mus musculus	NM_010735	MMU16984

Rat	Rattus norvegicus	NM_080769	BX883046

Woo	Mar	AF095

Common name	Species	LTA	LTB

dchuck	mota monax	586	AF095587

Human	Homo sapiens	AY216498	AY216497


miRNA	Regulation [17]	Potential regulation mechanism [17, 18]	Class [17]

miR-9-5p	Up	Chromosomal gain (1q)	Late

miR-15b-5p	Up	Chromosomal gain (3q)	Late

miR-28-5p	Up	Chromosomal gain (3q)	Early continuous

miR-100-5p	Down	Chromosomal loss (11q)	Late

miR-125b-5p	Down	Chromosomal loss (11q)	Late

miR-149-5p	Down	DNA methylation	Early continuous

miR-203a-3p	Down	DNA methylation	Early continuous

miR-375	Down	DNA methylation	Late

miRNA	Regulation [17]	Potential regulation mechanism [17, 18]	Class [17]

miR-9-5p	Up	Chromosomal gain (1q)	Late

miR-15b-5p	Up	Chromosomal gain (3q)	Late

miR-28-5p	Up	Chromosomal gain (3q)	Early continuous

miR-100-5p	Down	Chromosomal loss (11q)	Late

miR-125b-5p	Down	Chromosomal loss (11q)	Late

miR-149-5p	Down	DNA methylation	Early continuous

miR-203	Down	DNA methylation	Early contin

miRNA	Regulation [17]	Potential regulation mechanism [17, 18]	Class [17]

a-3p			uous

miR-375	Down	DNA methylation	Late


Animal	Skin non-midge fed**	Skin midge fed***	Tonsil	Lips	Lung

Sheep VH56/ 3 dpi	Minor engorgement, with indistinct vacuolation of epidermal cells.	Mildly oedematous/focal epidermal crusts/mild dermal inflammation *(lymphocytes, plasma cells and eosinophils).	Epithelial cells markedly vacuolated. Low numbers of eosinophils in tonsil itself.	Oedematous (especially around capillaries) and inflamed* (lymphocytes, plasma cells and eosinophils). Indistinct vacuolation of lip epidermal cells.	Peribronchial connective tissue is markedly oedematous and moderately inflamed*(lymphocytes, plasma cells and eosinophils).

Sheep VH67/ 4 dpi	Moderate oedema around capillaries and mild engorgement, mild aggregation of plasma cells around capillaries.	Moderately oedematous, especially around capillaries, with mild engorgement. Mild aggregation of plasma cells around capillaries, low numbers of neutrophils and eosinophils. Focal collagen necrosis.Note: C. sonorensis were last fed on this sheep 48 h prior to collection of skin samples.	Epithelial cells markedly vacuolated. Moderate numbers of eosinophils in connective tissue just below epithelium.	Focally dense aggregates of lymphocytes and plasma cells especially around capillaries and adnexae in mid dermis, lighter inflammation in superficial dermis.	Moderate inflammation *(lymphocytes, plasma cells) of peribronchial connective tissue.

Sheep VH58/ 6 dpi	Mild oedema and moderate engorgement, sparse dermal inflammation *(neutrophils, lymphocytes, plasma cells)	Moderately oedematous and engorged, with focal degeneration of epidermis. Moderate to marked diffuse dermal inflammation (Figure 2a) *(lymphocytes, plasma cells, eosinophils), with scattered foci of, predominantly, eosinophils associated with collagen necrosis.	Epithelial cells vacuolated. Glassy appearance to nuclei of macrophages, lymphocytes, plasma cells in lymphoid parenchyma.	Oedematous (especially around capillaries) and inflamed *(lymphocytes, plasma cells, eosinophils) – focally markedly so. Indistinct vacuolation of epidermal cells, but also apoptosis, epidermal oedema and erosion.	Peribronchial connective tissue is moderately oedematous and moderately inflamed *(plasma cells, lymphocytes).

Sheep VH57/ 8 dpi	Moderate oedema with mild perivascular inflammation *(lymphocytes and plasma cells).	Markedly oedematous (dermis and epidermis). Moderate to marked diffuse dermal inflammation around capillaries *(plasma cells, lymphocytes, eosinophils, neutrophils). Some crusts of surface and dermal foci of macrophages, plasma cells, lymphocytes and eosinophils, including granulomas in superficial dermis (neutrophils and eosinophils centrally with encircling epithelioid macrophages (Figure 2b).	Epithelial cells moderately to markedly vacuolated, numerous lymphocytes and plasma cells in epidermis. Glassy appearance to nuclei of macrophages, lymphocytes and plasma cells in lymphoid parenchyma.	Moderately oedematous (especially around capillaries) and moderately inflamed *(plasma cells, lymphocytes, rarely eosinophils).	Peribronchial connective tissue moderately oedematous and moderately inflamed *(plasma cells, lymphocytes). Diffuse engorgement and congestion.

Sheep VH66/ 9 dpi	Minor vacuolation of deep sweat gland cells as well as mild oedema with mild perivascular inflammation *(lymphocytes and plasma cells).	Moderate perivascular oedema and engorgement with patchy haemorrhage. One capillary contained a fibrin thrombus. Moderate to marked inflammation (plasma cells, lymphocytes, eosinophils, and neutrophils).	Areas of markedly vacuolated epithelial cells. There are also areas containing large numbers of lymphocytes and plasma cells in the tonsillar epithelium.	Engorged, haemorrhagic and oedematous (especially around capillaries) with mild inflammation *(plasma cells, lymphocytes, eosinophils and macrophages). Endothelial cells in the walls of some capillaries are degenerate.	Modest peribronchial inflammation *(plasma cells lymphocytes). Mild oedema, moderate engorgement, small numbers of vessels contain fibrin thrombi.


Attribute	Number (%)

Age

Mean Age	40.6 years

Standard deviation	9.1 years

Marital status (N = 220)

Married	229 (71.5)

Single	45 (14.1)

Widowed	49 (14.4)

Religion (N = 316)

Islam	182 (57.6)

Christian	134 (42.4)

Education (N = 300)

None	8 (2.7)

Primary	109 (36.3)

Secondary	155 (51.7)

Post-secondary	28 (9.3)

Ethnicity

Yoruba	284 (89.3)

Igbo	26 (8.2)

Hausa	8 (2.5)


Category	Frequency	%

Gender

Female	91	49.2

Male	94	50.8

Age

≤6 months	8	4.3

>6 months	176	95.7

Gestational age

>38 weeks	78	42.4

27-34 weeks	34	18.5

34-38 weeks	72	39.1

Birth weight

<1500g	20	10.9


gene	forward primer	reverse primer	probe

HPRT	5′-tgaacgtcttgctcgagatgtg-3′	5′-ccagcaggtcagcaaagaattt-3′	5′-tgggaggccatcacattgtagcc-3′

SNCA	5′-ccaaagagcaagtgacaaatgttg-3′	5′-agccagtggctgctgcaat-3′	5′-tgacgggtgtgacagcagtagccca-3′

5HT3AR	5-ggctggtgcacaagcaagac-3′	5-ggctggtgcacaagcaagac-3′	5-ctgcttggctgcgtcacctggttct-3′

5HT4R	5′-attccgggttgaacccttttc-3′	5′-aggtcttcggtagcgctcatc-3′	5′-acgtgccttcctcatcatcctct-3′

M3R	5′-cagctgcatacccaaaaccttt-3′	5′-tgaatgttttgttgcacagagcata-3′	5′-caacagcaccgtgaaccccgtgtg-3′

VIP	5′-aataaggcccagctccttgtg-3′	5′-cccaacctgagagcagaaggt-3′	5′-cttctcacagacttcggcatggc-3′

gene	forward primer	reverse primer	probe

5HT4R	5′-attccgggttgaacccttttc-3′	5′-aggtcttcggtagcgctcatc-3′	5′-acgtgccttcctcatcatcctct-3′

M3R	5′-cagctgcatacccaaaaccttt-3′	5′-tgaatgttttgttgcacagagcata-3′	5′-caacagcaccgtgaaccccgtgtg-3′

VIP	5′-aataaggcccagctccttgtg-3′	5′-cccaacctgagagcagaaggt-3′	5′-cttctcacagacttcggcatggc-3′


Property	Water	Blood	Units

Density ρ	1000	1050 [25]	kg/m3

Specific heat c	4190 [26]	3850 [25]	J/(kg · K)

Thermal conductivity k	0.61 [27]	0.53 [28]	W/(m · K)

Thermal diffusivity α = k/ρc	1.4 × 10-7	1.3 × 10-7	m2/s

Absolute viscosity μ	7 × 10-4 [26]	3.5 × 10-3 [29]	Pa · s

Kinematic viscosity ν = μ/ρ	7 × 10-7	3.3 × 10-6	m2/s

Coefficient of thermal expansion β	2.1 × 10-4 [26]	4.0 × 10-4 [30]	K-1

Property

Density ρ

Specific heat c

Thermal conductivity k

Thermal diffusivity α = k/ρc

Absolute viscosity μ

Kinematic viscosity ν = μ/ρ

Coefficient of thermal expansion β


Source

Among Pops

Among Indiv

Within Indiv

Total


	Screening or Intervention (Dependent Variable)

	Asked about AOD use

Independent Variable	OR [95% CI]

MHI-5 Score (0–100)	1.01 [1.00–1.01]

PESQ Risk Flags

Red (vs. Green)	1.69 [1.19–2.40]**

Yellow (vs. Green)	1.36 [0.96–1.92]

Age	1.25 [1.17–1.34]***

Gender

Female (vs. Male)	1.19 [0.93–1.52]

Race

Black (vs. White)	0.42 [0.27–0.66]***

Hispanic (vs. White)	0.40 [0.26–0.64]***

Multi/Other (vs. White)	0.56 [0.31–0.99]*

Mother’s Education

At least some college (vs. less than college)	1.07 [0.81–1.41]

Clinic

Clinic A (vs. Clinic D)	0.80 [0.52–1.26]

Clinic B (vs. Clinic D)	0.66 [0.43–1.02]

Clinic C (vs. Clinic D)	0.87 [0.54–1.40]


Rank	Feature description

1	Cumulative number of 30-day readmissions

2	Presence of acute respiratory failure ICD-9 code

3	Number of abnormal sodium level laboratory tests

4	Presence of pneumonia (organism unspecified) ICD-9 code

5	Number of abnormal chloride level laboratory tests

6	Presence of acute kidney failure (unspecified) ICD-9 code

7	Presence of diabetes (with other specified manifestations) ICD-9 code

8	Presence of acute kidney failure (any) ICD-9 code

9	Presence of respiratory failure, WKF

10	Presence of disorders of fluid electrolyte and acid-base balance (any) ICD-9 code

11	Presence of disorders of fluid/electrolyte/acid-base, WKF

12	Number of abnormal albumin level laboratory tests

13	Presence of asphyxia and hypoxemia ICD-9 code

14	Presence of anemia of chronic illness ICD-9 code

15	Presence of hypokalemia ICD-9 code

Feature description

Cumulative number of 30-day readmissions

Presence of acute respiratory failure ICD-9 code

Number of abnormal sodium level laboratory tests

Presence of pneumonia (organism unspecified) ICD-9 code

Number of abnormal chloride level laboratory tests

Presence of acute kidney failure (unspecified) ICD-9 code

Presence of diabetes (with other specified manifestations) ICD-9 code

Presence of acute kidney failure (any) ICD-9 code

Presence of respiratory failure, WKF

Presence of disorders of fluid electrolyte and acid-base balance (any) ICD-9 code

Presence of disorders of fluid/electrolyte/acid-base, WKF

Number of abnormal albumin level laboratory tests

Presence of asphyxia and hypoxemia ICD-9 code

Presence of anemia of chronic illness ICD-9 code

Presence of hypokalemia ICD-9 code


Location	Number

Spleen	14

Liver	13

Kidney	2

Diaphragm	2

Pancreas	2


Measure	Whole sample

N	Range	Mean	SD

Social isolation	2061	0–24	3.29	4.35

Loneliness	2051	0–8	1.57	1.94

Depression	2063	0–9	1.81	2.97


Tap	Channel A	Channel B	Doppler

Relative Delay (ns)	Average Power (dB)	Relative Delay (ns)	Average Power (dB)	Spectrum

1	0	0.0	0	–2.5	Classic

2	310	–1.0	300	0	Classic

3	710	–9.0	8900	–12.8	Classic

4	1090	–10.0	12,900	–10.0	Classic

5	1730	–15.0	17,100	–25.2	Classic

6	2510	–20.0	20,000	–16.0	Classic

Tap	Channel A	Channel B	Doppler

Relative Delay (ns)	Average Power (dB)	Relative Delay (ns)	Average Power (dB)	Spectrum

6	2510	–20.0	20,000	–16.0	Classic


 	Invasive fungal rhinosinusitis with orbital complications (n = 35)	Bacterial rhinosinusitis with orbital complications (n = 65)	Adjusted odds ratio (95% CI)	P value

Nasal crust	14	1	77.78 (1.95–3095.00)	<0.001

Oculomotor nerve involvement	34	45	15.11 (2.16–644.26)	0.001

Trochlear nerve involvement	33	43	5.70 (0.52–62.57)	0.10

Optic nerve involvement	22	17	3.77 (1.50–9.50)	0.002

Abducens nerve involvement	33	45	3.70 (0.40–34.57)	0.22

Facial swelling	10	8	2.37 (0.82–6.80)	0.10

Trigeminal nerve involvement	16	13	1.62 (0.77–3.42)	0.20

Pus in middle meatus	16	27	1.36 (0.57–3.25)	0.49

Swelling of middle meatus	28	31	1.29 (0.55–3.04)	0.56

Secretion in nasopharynx	4	10	0.56 (0.18–1.73)	0.31

Proptosis	27	45	0.53 (0.16–1.79)	0.30

Periorbital swelling	20	58	0.32 (0.12–0.83)	0.01

Chemosis	27	53	0.26 (0.06–1.18)	0.06

	Invasive fungal rhinosinusitis with orbital complications (n = 35)	Bacterial rhinosinusitis with orbital complications (n = 65)	Adjusted odds ratio (95% CI)	P value

Optic nerve involvement	22	17	3.77 (1.50–9.50)	0.002

Abducens nerve involvement	33	45	3.70 (0.40–34.57)	0.22

Facial swelling	10	8	2.37 (0.82–6.80)	0.10

Trigeminal nerve involvement	16	13	1.62 (0.77–3.42)	0.20

Pus in middle meatus	16	27	1.36 (0.57–3.25)	0.49

Swelling of middle meatus	28	31	1.29 (0.55–3.04)	0.56

Secretion in nasopharynx	4	10	0.56 (0.18–1.73)	0.31

Proptosis	27	45	0.53 (0.16–1.79)	0.30

Periorbital swelling	20	58	0.32 (0.12–0.83)	0.01

Chemosis	27	53	0.26 (0.06–1.18)	0.06


Group	(1a) Ultramutated POLE mutant	(1b) Hypermutated dMMR/MSI	(2) CIN/SCNA-high, MSS

Mutation rate	++++	+++	+

Somatic copy number alterations	+/−	+	+++

Key molecular/genetic abnormality	POLE EDM proofreading mutation	Defective MMR/MLH1 promoter hypermethylation	Variety of mutated cancer genes; WNT pathway activation (mostly by APC mutation/inactivation)

Predominant histological type	Moderately differentiated adenocarcinoma	Mucinous, or signet ring, or poorly differentiated adenocarcinoma	Moderately differentiated adenocarcinoma

Proportion of all colorectal carcinomas	∼3 %	∼13 %	∼84 %

Prognosis	Good (more data required)	Good/poor after relapse	Good-poor (depending on other characteristics)


	N0S0	N0Sπ

	HH	LL	LH	HL	HH	LL	LH	HL

Obs. 1	Limited**				Limited**	Super*	Super

Obs. 2	Limited**	Limited**		Super	Limited**	Super		Limited**

Obs. 3	Limited**	Limited**	Limited**	Limited*		Super**	Super

Obs. 4	Limited**		Limited**	Limited**	Limited**	Super

	N0S0

	HH	LL

Obs. 1	Limited**

Obs. 2	Limited**	Limited**

Obs. 3	Limited**	Limited**

Obs. 4	Limited**

N0S0	N0Sπ

LH	HL	HH	LL	LH	HL

		Limited**	Super*	Super

	Super	Limited**	Super		Limited**

Limited**	Limited*		Super**	Super

Limited**	Limited**	Limited**	Super


Regimens of first-line chemotherapy	Overall	MTB or MK infection

		(+)	(–)

	N = 30	N = 7	N = 23

Intensive regimens	26	6	20

 FOLFOX	8	2	6

 FOLFOX + Bmab	6	1	5

 FOLFIRI	6	1	5

 FOLFOX + Pmab/Cmab	2	2	0

 FOLFIRI + Pmab/Cmab	2	0	2

 FOLFIRI + Bmab	1	0	1

 XELOX	1	0	1

Non-intensive regimens	4	1	3

 UFT/LV	1	1	0

 S-1	2	0	2

 Capecitabine	1	0	1

Response rate (%)	40.0	28.6	43.5

 CR	1	1	0

 PR	11	1	10

 SD	10	2	8

 PD	7	3	4

 NE	1	0	1

Regimens of first-line chemotherapy	Overall	MTB or MK infection

		(+)	(–)

	N = 30	N = 7	N = 23

Intensive regimens	26	6	20

FOLFOX	8	2	6

FOLFOX + Bmab	6	1	5

FOLFIRI	6	1	5

FOLFOX + Pmab/Cmab	2	2	0

FOLFIRI + Pmab/Cmab	2	0	2

FOLFIRI + Bmab	1	0	1

XELOX	1	0	1

Non-intensive regimens	4	1	3

UFT/LV	1	1	0

S-1	2	0	2

Capecitabine	1	0	1

Response rate (%)	40.0	28.6	43.5

CR	1	1	0

PR	11	1	10

SD		2	8


Activity against the Isolates

Antibiotics	Resistance Prevalence (%)	MIC (mg L−1)

Range	50%	90%

Ampicillin (AMP)	100.0	64 to ≥1024	1024	1024

Amoxicillin (AMO)	100.0	1 to ≥1024	1024	1024

Streptomycin Sulfate (STR)	92.3	1 to ≥1024	128	512

Trimethoprim (TRI)	98.0	8 to ≥1024	1024	1024

Chloramphenicol (CHL)	100.0	256 to ≥1024	1024	1024

Sulfonamide (SUL)	100.0	512 to ≥1024	1024	1024

Tetracycline (TET)	90.6	2 to ≥512	128	256

Oxytetracycline (OXY)	90.6	1 to ≥1024	256	512

Nalidixic Acid (NAL)	73.6	1 to ≥1024	512	1024

Erythromycin (ERY)	92.5	4 to ≥1024	128	512

Spiramycin (SPIRA)	90.6	2 to ≥1024	512	1024

Kanamycin (KAN)	54.7	1 to ≥1024	128	1024

Activity against the Isolates

Antibiotics	Resistance Prevalence (%)	MIC (mg L−1)

Range	50%

Ampicillin (AMP)	100.0	64 to ≥1024	1024

Amoxicillin (AMO)	100.0	1 to ≥1024	1024

Streptomycin Sulfate (STR)	92.3	1 to ≥1024	128

Trimethoprim (TRI)	98.0	8 to ≥1024	1024

Chloramphenicol (CHL)	100.0	256 to ≥1024	1024

Sulfonamide (SUL)	100.0	512 to ≥1024	1024

Tetracycline (TET)	90.6	2 to ≥512	128

Oxytetracycline (OXY)	90.6	1 to ≥1024	256

Nalidixic Acid (NAL)	73.6	1 to ≥1024	512

Erythromycin (ERY)	92.5	4 to ≥1024	128

Spiramycin (SPIRA)	90.6	2 to ≥1024	512

Kanamycin (KAN)	54.7	1 to ≥1024	128


Characteristics, n (%)	Participants completing the SF-6D	Participants completing the EQ-5D-3L

(N = 1021)	(N = 1015)

Employed or self-employed	659 (64.5)	643 (63.4)

General health status

Poor	4 (0.4)	8 (0.8)

Fair	70 (6.9)	99 (9.8)

Good	443 (43.4)	424 (41.8)

Very good	419 (41.0)	383 (37.7)

Excellent	85 (8.3)	101 (10.0)

Self-reported health on EQ-5D-3L VAS, Mean (SD)	84.5 (11.2)	83.0 (12.1)


Study	Year	N	Criteria	Treatment	Findings

Hu et al. [6]	2006	84	Solitary brain metastasis	SRS or surgery	Stage I intrathoracic patients had better OS outcomes than stage III

Bonnette et al. [7]	2001	108	Brain metastasis (98 with solitary)	Surgery	Adenocarcinoma, T stage, complete resection with better outcomes

Rodrigues et al. [8]	2011	66	≤6 intracranial lesions	Image-guided SIB RT	Presence of systemic disease, lower performance status correlated with decreased OS

Iwasaki et al. [9]	2004	41	Solitary brain metastasis	Resection of primary site and brain metastasis	Risk score criteria for improved OS:adenocarcinoma, node-negative, normal CEA level

Mussi et al. [10]	1996	52	Solitary brain metastasis	Resection of primary site and brain metastasis	No status, lobectomy associated with decreased OS. 5-year OS in patients with synchronous/metachronous lesions 6.6/19%, respectively

Machiarini et al.[11]	1991	37	Solitary brain metastasis. Synchronous (<1 month) and metachronous included.	Resection of primary site and brain metastasis	Most frequent site of first recurrence was ipsilateral thorax (n = 14) and brain (n = 6). The receipt of adjuvant chemotherapy was strongest predictor of disease-free interval

Wronski et al. [12]	1995	231	Single (87%) or multiple (13%) metastatic intracranial lesions	Resection	Female gender, complete location, infratentorial location, no systemic metastases, age < 60 years associated with improved OS


	Average weekly doses (IU/kg)

Population by	Weeks 12–24

Frequency of administration	n (%)	Mean ± SD

3× per week	158 (100.0)	103.5 ± 88.0

2× per week	150 (100.0)	76.9 ± 58.5

1× per week	103 (100.0)	65.9 ± 57.8

Dialysis type

Predialysis	32 (100.0)	87.7 ± 73.5

Haemodialysis	288 (100.0)	82.3 ± 57.9

Peritoneal dialysis	91 (100.0)	89.8 ± 107.3

Total	411 (100.0)	84.4 ± 72.7


	Diabetic (N = 8)	Non-diabetic (N = 60)	p value

Days till admission, median (range)	4 (0–49)	15 (0–49)	0.367

Referral, No (%)			0.088

 Admission to hospital > 1 day	7 (87.5)	49 (81.7)

 Admission to hospital refused by patient	1 (12.5)	0 (0.0)

 Day treatment	0 (0.0)	11 (18.3)

Additional hospitalization, No (%)a	1 (12.5)	8 (13.6)	1.000

Median length of stay, days (range)	20 (4–41)	5 (1–30)	0.025

Complications, No (%)b	5 (62.5)	10 (17.5)	0.013

Treatment, No (%)a			0.549

 Graft	7 (87.5)	54 (91.5)

 Necrotectomy only	0 (0.0)	1 (1.7)

 Conservative	1 (12.5)	4 (6.8)

Additional surgery, No (%)a	2 (25.0)	4 (6.8)	0.147

Complete epithelialization after first treatment, No (%)c	6 (85.7)	45 (83.3)	1.000

Days till complete epithelialization, median (range)	44 (17–93)	31 (10–192)	0.660

Take graft, No (%)d

			0.365

 Good	6 (75.0)	48 (85.7)

 Moderate	1 (12.5)	4 (7.1)

 Inapplicable	1 (12.5)	4 (7.1)


	Univariate analysis	Multivariate analysis

p-value	OR (95% CI)	p-value	OR (95% CI)


Angiographic result	Total (n = 108) (%)	Anterior circulation (n = 92) (%)	Posterior circulation (n = 16) (%)

mTICI 0	8 (7.4)	4 (4.4)	4 (25)

mTICI 1	8 (7.4)	7 (7.6)	1 (6.3)


Method	Phen. allowed a	Input values b	Kc	Link

Ref-based	Any	Beta	N/A	http://people.oregonstate.edu/~housemae/software/TutorialLondon2014

				http://bioconductor.org/packages/release/bioc/html/minfi.html

Ref-free	Any	Beta	Estimated	http://cran.r-project.org/web/packages/RefFreeEWAS/index.html

SVA	Any	Beta or logit(beta)	Estimated	http://bioconductor.org/packages/release/bioc/html/sva.html

ISVA	Continuous	Beta or logit(beta)	Estimated	http://cran.r-project.org/web/packages/isva/index.html

EWASher	Binary	Beta	Estimated	http://research.microsoft.com/en-us/downloads/472fe637-7cb9-47d4-a0df-37118760ccd1

CellCDec	Not used	Beta	Input	https://github.com/jameswagner/CellCDec

Deconf	Not used	Beta or logit(beta)	Input	http://web.cbio.uct.ac.za/~renaud/CRAN

RUV	Any	Beta or logit(beta)	Estimated	https://cran.r-project.org/web/packages/ruv/index.html


Material	Fixation method	Approximate global size (mm)	Maximum deviation factor	Minimum size factor	Number of elements

Cement	—	2.0	0.02	0.1	107556

Femoral prosthesis	—	1.5	0.05	0.1	631470

Femur	Cemented	2.0	0.05	0.1	761218

Noncemented	2.0	0.05	0.1	792849

Total number of elements	Cemented	—	—	—	1500244

Noncemented	—	—	—	1424319


Facies type	Model	Nugget	Partial sill	Range (m)

Sand flats	Exponential	0.103	0.223	3015

Mixed flats	Spherical	0.186	0.065	1029

Mud flats	Spherical	0.099	0.295	7575


GCA Classification Criteria

(1) Age at onset ≥50 years

(2) A new headache

(3) Temporal artery abnormality such as tenderness to palpation or decreased pulsation

(4) Erythrocyte sedimentation rate ≥50 mm/h

(5) Abnormal artery biopsy showing vasculitis with mononuclear cell or granulomatous inflammation, usually with giant cells


Items	Issues

Model units	• Headcounts do not reflect variation in effective workforce.• FTE measured in working hours can translate into a variable effective workforce.• FTE defined in reference to the most active physician category makes the assumption that the activity level in that category is relevant.

Data quality	• Routine data are useful, but provide generally limited information.• Various data sources coexist, with inconsistencies between them.• Qualitative data for in-depth understanding of trends is often lacking.

Categories of resources	• Computation of human resources requirements by specialty obviates professional interactions and skill mix.• Assessing skill-mix requirements is a complex task and documentation is often lacking.

Supply parameters	• Information other than age, sex and services volume is often unavailable.• Productivity is sensitive to the working and societal environment and is rapidly evolving.

Demand parameters	• Assessing the impact of new technologies, emerging pathologies and demographic changes requires a large quantity of data and expertise that are often unavailable.• Level and mode of health care utilization are sensitive to the environment and are rapidly evolving.

Modeling	• Deterministic models are likely to generate inaccuracies without providing a means to evaluate them.• Regression modeling with stochastic simulation can be innovative in the HRH field but background is lacking• Regular updating of data is paramount but resource-consuming.


Variable	N	%

Age in years (n = 1533)

 15–19	15	1

 20–29	455	29.7

 30–39	710	46.3

 40–49	242	15.8

 50 and above	111	7.2

Sex (n = 1549)

 Female	1333	86.1

Caregiver relationship to a child (n = 1546)

 Mother	1257	81.3

 Father	130	8.4

 Relative	159	10.3

Marital status (n = 1546)

 Married	1210	78.3

 Single, separated or divorced	179	11.5

 Widow or widower	157	10.2

Education level (n = 1546)

 None or informal	170	11.0

 Primary	285	18.4

 Secondary	703	45.5

 Postsecondary Diploma and above	388	25.1

Employment status (n = 1532)

 None	326	21.3

 Employed in informal sector	988	64.5

 Employed in formal sector	218	14.2

Income status (n = 1474)

 <N18,000	914	62.0

 N18,000–50,000	427	29.0

 N51,000–100,000	105	7.1

 >N100,000	28	1.9


Category	Subcategory	Cases	Monocytes(/mm3)	P value

			<545	≥545

Gender	Male	310	115	195	0.102

	Female	41	20	21

Age	<50 years	268	102	166	0.418

	≥50 years	83	33	50

HBsAg	Negative	49	14	35	0.083

	Positive	302	121	181

AFP(ng/ml)	<200	161	61	100	0.463

	≥200	190	74	116

Edmonson grading	I-II	271	107	164	0.278

III-IV	80	28	52

Tumor size	<5 cm	70	35	35	0.019

≥5 cm	281	100	181

Surgical margin	<1 cm	122	44	78	0.289

≥1 cm	229	91	138

Liver cirrhosis	Absent	82	29	53	0.3

Present	269	106	163

PVTT	Absent	278	108	170	0.44

	Present	73	27	46

Capsulation	Capsulated	224	92	132	0.111

Non-caspulated	127	43	84

Tumor number	Single	276	107	169	0.465

Multiple	75	28	47

Macrovascular invasion	Absent	261	102	159	0.391

	Present	90	33	57

Capsulation	Non-caspulated	127	43	84

Tumor number	Single	276	107	169	0.465

Multiple	75	28	47

Macrovascular invasion	Absent	261	102	159	0.391

	Present	90	33	57


Collection time	AKI (renal replacement)	Mean	Std	p-value

T1 preoperative	No	1,0	,27	0,06

Yes	1,24	,43

T2 start CBP	No	,80	,21	0,07

Yes	,96	,31

T3 20 minutes after CBP start	No	,89	,21	0,06

Yes	1,05	,32

T4 OP-end	No	1,00	,26	0,03

Yes	1,22	,30

T5 24 h postoperative	No	1,26	,52	0,002

Yes	1,93	,47

T6 discharge(max. day 6)	No	1,28	,40	0,001

 	Yes	2,09	,57

Collection time

T1 preoperative

T2 start CBP

T3 20 minutes after CBP start

T4 OP-end

T5 24 h postoperative

T6 discharge(max. day 6)


Model	Standardized coefficients	t	Sig.	95.0 % confidence interval for B

Beta	Lower bound	Upper bound

(Constant)		−12.353	<0.001	−1.67	−1.21

Educational level of mothers	0.08	3.273	0.001	0.06	0.23

Appropriate complementary feeding score	0.04	1.927	0.05	−0.002	0.27

Diarrhoeal infection	0.10	4.499	<0.001	0.14	0.35

Gender of child	0.05	2.209	0.03	0.012	0.209


Phytochemical	Name of the tests	Observed changes	Result

Alkaloids	Mayer's test	Creamy white precipitate	−

Hager's test	Yellow crystalline precipitate	 +

Wagner's test	Brown or deep brown precipitate 	−

Dragendorff's test	Orange or orange-red precipitate	−

Tannic acid test	Buff color precipitate	−

Carbohydrates	Molisch's test	A red or reddish violet ring is formed at the junction of two layers and on shaking a dark purple solution is formed	+

Barfoed's test (general test for monosaccharides)	Red precipitate	−

Fehling's test	A red or brick-red precipitate	−

Benedict's test	 	+

Test for combined reducing sugar	A brick-red precipitate	−

Glycosides	General test	Yellow color	−

Bromine water test 	yellow precipitate	+

Test for glucoside	Production of brick-red precipitation (carried out with the hydrolyzed extract)	−

Flavonoids	Alkaline reagent test	Red color	+/−

Shinoda test (magnesium hydrochloride reduction test)	Green to blue color	+

Zinc hydrochloride reduction test	Red color after few minutes 	−

Saponins	Frothing test	Formation of stable foam	+

Steroids	Libermann-Burchard's test	Greenish color	−

Tannins	Lead acetate test	A yellow or red precipitate	 +

Ferric chloride test	Blue green color	−

Alkaline reagent test	Yellow to red precipitate	+

Terpenoids	Salkowski test	Yellow color appears at the lower layer 	−

Phytochemical	Name of the tests	Observed changes	Result

Saponins	Frothing test	Formation of stable foam	+

Steroids	Libermann-Burchard's test	Greenish color	−

Tannins	Lead acetate test	A yellow or red precipitate	+

Ferric chloride test	Blue green color	−

Alkaline reagent test	Yellow to red precipitate	+

Terpenoids	Salkowski test	Yellow color appears at the lower layer	−


Dynesys group (n = 95)	PLIF group (n = 81)	p


Analyte

Paeoniflorin sulfonate (12)

Albiflorin (2)

Paeoniflorin (1)

Liquirtin apioside (5)

Liquiritin (3)

Isoliquiritin apioside (6)

Isoliquiritin (4)

Liquiritigenin (8)

Isoliquiritigenin (9)

Glycyrrhizic acid (10)

Glycyrrhetinic acid (11)

Ginsenoside Rb1 (IS1)

Swertiamarin (IS2)

Kaempferol-3-O-rutinoside (IS3)


Strength of interaction	Definition

Strong	A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a substrate for that CYP by equal to or more than 5-fold (or >80% decrease in clearance)

Moderate	A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 5-fold but equal to or more than 2-fold (or 50%–80% decrease in clearance)

Weak	A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 2-fold but equal to or more than 1.25-fold (or 20%–50% decrease in clearance)

Strength of interaction	Definition

Moderate	A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 5-fold but equal to or more than 2-fold (or 50%–80% decrease in clearance)

Weak	A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 2-fold but equal to or more than 1.25-fold (or 20%–50% decrease in clearance)


Annotation category	Resource	Comments

Genomic	GENCODE	Variant classification and mapping to gene

	Human DNA Repair Genes	Curated list from [40]

Protein	UniProt	Protein-specific annotation

	dbNSFP	Conservation and prediction scores

Cancer variant	COSMIC	Catalogue of Somatic Mutations in Cancer

Non-cancer variant	1000 Genomes Project	Germline SNVs

Annotation category	Resource	Comments

Non-cancer variant	1000 Genomes Project	Germline SNVs


Country	Sample Size SpA	Sample Size (Control)	Prevalence in Population	Prevalence in SpA	Prevalence in AS	OR AS/GP [95% CI]	Reference

Algeria	129 AS (ESSG and NY)	76 healthy blood donors	4%		69%	54.14 [16.09–182.18]	[17]

Egypt		380 normal individuals	4.7%				[18]

Egypt	75 SpA (ESSG) including 34 AS			58.7%			[19]

Egypt		100 healthy controls	1%				[20]

Iraq	25 AS		2.1%		84%		[21]

Iran	60 AS	430 healthy blood donors	3.95%		66.67%	48.59 [23.57–100.17]	[22]

Iran	119 AS				68.91%		[23]

Iran	98 AS (NY)				73.4%		[24]

Israel	38 AS	456 normal individuals	3%		79%		[25]

Jordan	22 AS (NY)				75%		[26]

Jordan / Qatar	129 AS	2579 healthy individuals	2.4%		72.22%	104.87 [66.21–166.11]	[12]

Kuwait	58 SpA (27 AS)			69.43%	82.56%		[27]

Kuwait	35 SpA + AS patients	544 controls	4%	25.7%		8.21 [3.44–19.60]	[28]

Lebanon	105 SpA (ESSG)24 AS (NY)	841 Rheumatolgy patients	1.44%	13.85%	26.32%	24.46 [7.78–68.19]	[29]

Morocco	46 AS + coxitis	183 healthy controls	6.16%		58.70%	22.09 [9.48–51.49]	[30]

Morocco	49 SpA (Amor and ESSG)				67%		[31]

Oman		321 healthy	0.3%				[32]

Qatar	119 AS (NY)				74%		[33]

Saudi Arabia	12 AS				66.67%		[34]

Syria	50 AS (NY)	217 healthy controls	1.4%		60%	105.64 [29.98–381.87]	[35]

Tunisia	365 AS and/or BD	124 controls	3.2%		42.9%		[36]

Tunisia	100 AS (NY)	100 healthy controls	3%		62%	52.75 [15.61–178.31]	[37]

Tunisia	50 AS (Amor / ESSG)				69%		[38]

Turkey	112 AS (NY)	55 controls	2.8–6.8%		70%	29.82 [9.99–89.05]	[39]

Turkey	216 AS (67 analyzed)				91%		[40]

UAE		760 healthy	6.4%				[41]

UAE	17 AS				56%		[42]

Country	Sample Size SpA	Sample Size (Control)	Prevalence in Population	Prevalence in SpA	Prevalence in AS	OR AS/GP [95% CI]	Reference

Algeria	129 AS (ESSG and NY)	76 healthy blood donors	4%		69%	54.14 [16.09–182.18]	[17]

Egypt		380 normal individuals	4.7%				[18]

Egypt	75 SpA (ESSG) including 34 AS			58.7%			[19]

Egypt		100 healthy controls	1%				[20]

I	25 AS		2.1%				[2

Country	Sample Size SpA	Sample Size (Control)	Prevalence in Population	Prevalence in SpA	Prevalence in AS	OR AS/GP [95% CI]	Reference

raq					84%		1]

Iran	60 AS	430 healthy blood donors	3.95%		66.67%	48.59 [23.57–100.17]	[22]

Iran	119 AS				68.91%		[23]

Iran	98 AS (NY)				73.4%		[24]

Israel	38 AS	456 normal individuals	3%		79%		[25]

Jordan	22 AS (NY)				75%		[26]

Jordan / Qatar	129 AS	2579 healthy individuals	2.4%		72.22%	104.87 [66.21–166.11]	[12]

Kuwait	58 SpA (27 AS)			69.43%	82.56%		[27]

Kuwait	35 SpA + AS patients	544 controls	4%	25.7%		8.21 [3.44–19.60]	[28]

Lebanon	105 SpA (ESSG)24 AS (NY)	841 Rheumatolgy patients	1.44%	13.85%	26.32%	24.46 [7.78–68.19]	[29]

Morocco	46 AS + coxitis	183 healthy controls	6.16%		58.70%	22.09 [9.48–51.49]	[30]

Morocco	49 SpA (Amor and ESSG)				67%		[31]

Oman		321 healthy	0.3%				[32]

Qatar	119 AS (NY)				74%		[33]

Saudi Arabia	12 AS				66.67%		[34]

Syria	50 AS (NY)	217 healthy controls	1.4%		60%	105.64 [29.98–381.87]	[35]

Tunisia	365 AS and/or BD	124 controls	3.2%		42.9%		[36]

Tunisia	100 AS (NY)	100 healthy controls	3%		62%	52.75 [15.61–178.31]	[37]

Tunisia	50 AS (Amor / ESSG)				69%		[38]

Turkey	112 AS (NY)	55 controls	2.8–6.8%		70%	29.82 [9.99–89.05]	[39]

Turkey	216 AS (67 analyzed)				91%		[40]

UAE		760 healthy	6.4%				[41]

UAE	17 AS				56%		[42]


Covariate	Relative risk	95 % CI	p value

p62	0.764	NS	0.619

Histological grading	1.239	NS	0.392

Lymph node metastases	0.794	NS	0.510

Tumour stage	1.647	NS	0.141

Distant metastases	3.176	1.453-6.940	0.004


Food	GI

Gluten-free bread	230

Gluten-free pasta	255

Quinoa	186


Laccase Isoform	Experimental Affinity Rank 1	HINT Score

Beta	1	430

Gamma	2	206

Delta	3	104


Variables	Number	All	Fish	Meat	Supplement	Pa


Isolates	Body site	spa type	SCCmec	STa	PFTb

27 N	nasal	t002	II	ST105	A1

08 N	nasal	t311	II	ST105	B1

P65N	nasal	t002	II	ST105	C

98I	groin	t14789	IVa	ST1176	D1

62 N	nasal	t149	I	ST5	E1

P32N	nasal	t37	III	ST239	F1

78 N	nasal	t110	I	ST105	G

111 N	nasal	t002	II	ST105	H

59 N	nasal	t149	IVa	ST1510	I

Isolates	Body site	spa type	SCCmec	STa	PFTb

27 N	nasal	t002	II	ST105	A1

08 N	nasal	t311	II	ST105	B1

P65N	nasal	t002	II	ST105	C

98I	groin	t14789	IVa	ST1176	D1

62 N	nasal	t149	I	ST5	E1

P32N	nasal	t37	III	ST239	F1

78	nas	t11	I	ST

Isolates	Body site	spa type	SCCmec	STa	PFTb

 N	al	0		105	G

111 N	nasal	t002	II	ST105	H

59 N	nasal	t149	IVa	ST1510	I


Year	Trade Specialization Index (TSI)

2001	-0.940

Year	Trade Specialization Index (TSI)

2006	-0.898

2010	-0.844


Features 	 DNA configurations

 A 	 B 	 Z

Helix orientation 	 Right-handed 	Right-handed 	Left-handed

DNA diameter 	 2.55 	 2.37 	 1.84

bp diameter 	 1.0 	1.0 	 0.6

bp axial step 	 0.23 	 0.33 	 0.38

Helix pitch 	 2.46 	 3.2 	 3.0

bp/helix turn 	 10.7 	 10 	 12

bp/nucleosome 	 286 	 198 	 172

Helix axial shift 	 0.76 	 1.2 	 0.77

Target angular aperture 	 87°	 73°	 60°

Target height 	 0.119 	 0.183 	 0.249

Total number of bp 	7.72 × 108	5.35 × 108	4.64 × 108

Target volume (nm3) 	 0.12 	 0.13 	 0.10

Features	A	B	Z

Helix orientation	Right-handed	Right-handed	Left-handed

DNA diameter	2.55	2.37	1.84

bp diameter	1.0	1.0	0.6

bp axial step	0.23	0.33	0.38

Helix pitch	2.46	3.2	3.0

bp/helix turn	10.7	10	12

bp/nucleosome	286	198	172

Helix axial shift	0.76	1.2	0.77

Target angular aperture	87°	73°	60°

Target height	0.119	0.183	0.249

Total number of bp	7.72 × 108	5.35 × 108	4.64 × 108

Target volume (nm3)	0.12	0.13	0.10


GOLD stage *	Number of patients (%)

Stage I	18 (17.0%)

Stage II	42 (39.6%)

GOLD stage *	Number of patients (%)

Stage III	28 (26.4%)

Stage IV	18 (17.0%)

Total LAA score †	Patient number (%)

7-12	46 (43.4%)

13-18	24 (22.6%)

19-24	36 (34.0%)


Kano Model	Refined Kano Model

Quality Attribute	High Important Attributes	Low Important Attribute

Attractive quality	High attractive quality	Low attractive quality

One-dimensional quality	High value-added quality	Low value-added quality

Must-be quality	Critical quality	Necessary quality

Indifferent quality	Potential quality	Care-free quality

Kano Model

Quality Attribute

Attractive quality

One-dimensional quality

Must-be quality

Indifferent quality

Refined Kano Model

High Important Attributes	Low Important Attribute

High attractive quality	Low attractive quality

High value-added quality	Low value-added quality

Critical quality	Necessary quality

Potential quality	Care-free quality